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ABSTRACT 
Alterations in Skeletal Muscle Arteriolar Vasoreactivity During the Progression of 
Type 2 Diabetes in the Zucker Diabetic Fatty Rat. (May 2004) 
Lisa Annmarie Lesniewski, B.S., The Ohio State University; 
M.A., Kent State University 
Chair of Advisory Committee: Dr. Michael D. Delp 
 
 
 Altered vasoreactivity and mechanical properties of skeletal muscle 
arterioles could impact peripheral insulin resistance and hypertension observed in 
type 2 diabetes.  The purpose was to determine if increased vasoconstrictor 
reactivity, decreased vasodilator reactivity and alterations in the structural 
properties of 1A arterioles from both high-oxidative and low-oxidative glycolytic 
skeletal muscles is present during prediabetes as well as acute and chronic diabetes, 
and to determine if this dysfunction precedes the development of elevated arterial 
pressure in type 2 diabetes.  Zucker Diabetic Fatty (ZDF) rats and lean age-matched 
controls were studied at 7 (prediabetes), 13 (acute diabetes) and 20 (chronic 
diabetes) weeks of age.  Following measurement of arterial pressure, 
vasoconstrictor responsiveness to norepinephrine (NE), potassium chloride (KCl), 
and increasing intraluminal pressure (MYO), vasodilator responsiveness to 
acetylcholine (ACh), sodium nitroprusside (SNP) and intraluminal flow and 
passive mechanical properties were examined in arterioles from soleus and 
gastrocnemius muscles.  Vasoconstriction to NE was enhanced in gastrocnemius 
muscle arterioles during prediabetes and preceded elevated arterial pressure.  
Alterations in the passive mechanical properties of arterioles from both muscles 
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were observed throughout the progression of diabetes.   Flow-induced vasodilation 
was decreased in the high-oxidative muscle arterioles during acute diabetes, and 
was coincident with the emergence of elevated arterial pressure.  During chronic 
diabetes, vasodilation to ACh and flow were reduced in soleus muscle arterioles.  
The reduced vasodilation to ACh was the result of a loss of NO. Although the 
vasodilator capacity of low-oxidative glycolytic skeletal muscle arterioles was not 
diminished throughout the progression of diabetes, the contribution of NO to ACh-
induced dilation was lost in the prediabetic and acute diabetic rats. The data 
demonstrate that alterations in both the vasoconstrictor and passive properties of 
low-oxidative glycolytic skeletal muscle arterioles are present during prediabetes, 
and precede the development of type 2 diabetes, and that although endothelial 
dysfunction does not become manifest in these skeletal muscle arterioles, 
alterations in the signaling mechanisms to achieve that vasodilation are present in 
prediabetes.  Moreover, overt type 2 diabetes results in endothelial dysfunction and 
altered mechanical properties in high-oxidative skeletal muscle arterioles.   
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CHAPTER I 
 
INTRODUCTION 
 Diabetes Mellitus, the sixth leading cause of death in the US, accounted for 
more than 193,000 deaths in 1997.  With a worldwide prevalence that is steadily 
increasing, a reported 151 million cases worldwide in the year 2000 is projected to 
increase in the next decade by 46%.  Of these individuals, approximately 90% are 
type 2 diabetics.  In the US alone, 16 million people are already affected, with an 
estimated 800,000 new cases each year.  This number is expected to increase to 23 
million within 10 years.  Alarmingly, another 200 million people worldwide suffer 
from some degree of glucose intolerance, and 40 % of these individuals are expected 
to progress to frank type 2 diabetes within 5-10 years.  Moreover, although once 
considered a disease of the middle aged and aged, its prevalence is increasing among 
our nations youth, mirroring the increase in obesity in that population.  This will 
undoubtedly place an enormous burden on our health care systems.  At present, the 
cost of diabetes-related health care has reached $105 billion annually, which accounts 
for one tenth of all US health care dollars and one quarter of all Medicare dollars 
spent. 
 With the advent of insulin therapy, diabetes is no longer a fatal ketotic disease, 
but rather leads to a number of serious morbidities that often develop slowly and 
insidiously over the duration of the disease.  The cardiovascular complications of 
diabetes are now the leading cause of morbidity and mortality in patients, and it is  
______________ 
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becoming evident that these complications have an onset much earlier than previously  
assumed.  The macrovascular complications of diabetes have been associated with 
hypertension, atherosclerotic disease, myocardial infarction and stroke.  
Microvascular complications are associated with retinopathy, neuropathy, and 
nephropathy, making diabetes the leading cause of blindness in adults aged 20-74, 
lower limb amputations, and end-stage renal failure.  The recognition that at least 40% 
of type 2 diabetics present with hypertension at the time of diagnosis led investigators 
to postulate that the cardiovascular complications of the disease, normally thought to 
be the consequence of prolonged disease duration, are actually beginning prior to the 
onset of overt diabetes during the preceding period of subclinical hyperglycemia and 
insulin resistance, termed prediabetes.  Moreover, vascular dysfunction may be both 
the cause and the consequence of insulin resistance as blood flow to insulin sensitive 
tissues, and subsequent insulin delivery, limits glucose uptake.  Thus, it is necessary to 
examine vascular function not only after the development of overt diabetes but also 
during this prediabetic period. 
 The purpose of this study was to examine alterations in microvascular 
function during the progression of type 2 diabetes from prediabetes to acute and 
chronic type 2 diabetes.  As the skeletal muscle is both an insulin-sensitive tissue 
and the largest sink for plasma glucose, dysfunction in this circulation can have 
profound implications on glucose uptake.  In addition, the skeletal muscle 
microvasculature is a large contributor to whole body vascular resistance, and 
alterations in its function could contribute to the hypertension often seen in 
prediabetic and type 2 diabetic individuals.  The skeletal muscle is not 
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homogeneous and can be characterized into several types, including high-oxidative 
and low-oxidative glycolytic.  These muscle fiber types differ in regards to their 
contractile characteristics, as well as blood flow, glucose uptake and insulin 
sensitivity profiles.  Differential alterations in the function of arterioles that supply 
blood to low-oxidative glycolytic and high-oxidative muscles have been found in 
other circumstances, e.g. normal physiological aging, and if present in type 2 
diabetes, could profoundly effect delivery of glucose not only to the skeletal muscle 
as a whole, but also its distribution within the muscle mass.  To examine this 
possibility, we studied the structure and function of resistance arteries that supply 
both predominately high-oxidative and predominately low-oxidative glycolytic 
locomotor skeletal muscles.   
 The specific aims of this study were to test the hypotheses that, 1) type 2 
diabetes will enhance myogenic responsiveness of resistance arterioles isolated 
from muscles composed of different fiber types, 2) type 2 diabetes will increase the 
passive stiffness of these skeletal muscle resistance arterioles, 3) type 2 diabetes 
increases responsiveness of skeletal muscle resistance arterioles to vasoconstrictor 
agonists, 4) type 2 diabetes will attenuate skeletal muscle arteriolar responsiveness to 
either endothelium-dependent or endothelium-independent vasodilator stimuli, and 5) 
that these changes will be present during the prediabetic state as well as during acute 
and chronic type 2 diabetes. 
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CHAPTER II 
REVIEW OF LITERATURE 
2.1 Discovery and Classification of Diabetes 
 Diabetes mellitus has been recognized for centuries; however until 1776 it was 
diagnosed solely on the clinical manifestations of thirst, excessive urination, hunger, 
weight loss, and muscle weakness (66).  An ancient physician, Arateaus of 
Cappadocia, first coined the term diabetes from the Greek for syphon owing to the 
excessive urine output of afflicted patients.  The sweet nature of the urine of diabetic 
patients was described in ancient times as well, specifically, diabetes was termed 
sweet pissing disease in ancient Hindu texts, although the substance in the urine that 
led to the sweet taste was not elucidated until much later.  Moreover, in the 17th 
century, Thomas Willis again made this same observation (i.e. sweet tasting urine), 
and coined the term diabetes mellitus, from the Greek for honey (41).  However, 
sugar was not revealed to be the source of the sweetness until 1776 when Dobson 
evaporated the urine of diabetic patients and found a residue that tasted like brown 
sugar.  Along with this discovery, Dobson also identified the presence of excess blood 
sugar in patients (41, 66).  Although the sugar was not identified as glucose until 
1815, the discovery of sugar in the urine allowed for a means of clinically diagnosing 
diabetes.  However, even with a means of biochemically diagnosing the disease, the 
mechanisms and/or organs responsible for the disease remained unknown.  
 The clinical manifestation of polyuria first led researchers to believe that the 
kidney was the seat of the disorder.  However, at the end of the 18th century Rollo 
demonstrated that the content of the diet influenced the amount of urinary sugar 
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excreted, then focusing attention to the gastrointestinal system (66).  However, the 
liver emerged as the most likely candidate, as Claude Bernard had recently described 
the livers glycogen stores and role in glucose excretion, leading investigators to 
surmise that diabetes was the result of disordered liver glucose excretion.  This 
contention was further supported by the work of Bernard and Schiff, who failed to 
induce diabetes following degeneration of the pancreas following occlusion of its 
secretory duct. 
 In 1889, Minkowski and Von Mering finally determined the pancreas to be the 
site of the disorder, when they were able to induce diabetes in a pancreatectomized 
dog.  A decade later, a secretion from the Islets of Langerhans was determined to be 
the anti-diabetogenic agent (67).  This secretion was not described as insulin until 
1921 by Fredrick Banting, Charles Best, J.J.R. Macleod and J. Bertram Collip, for 
which Banting and Macleod were awarded the Nobel Prize less than three years later 
(67).  In the following year, the first successful insulin treatment of a diabetic human 
began on a 14 year old patient, Leonard Thompson.  Before insulin therapy, the life 
expectancy of a type I diabetic patient was less than 12 months, with insulin therapy, 
Thompson lived to age 59 when he died of cancer (67).  However, it became apparent 
that insulin therapy was not effective in all diabetic patients, suggesting possible 
subgroups of the disease. 
 During the time of the elucidation of the pancreas as the diseased organ, some 
physicians began to note differences in the etiology of the disease among their 
patients.  In 1875, Bouchardat compiled findings published over 35 years which 
described at least two forms of diabetes, one in the young, presenting acutely with 
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dramatic weight loss, and one in older adults who tended to be overweight.  These 
findings were later confirmed by Lancereauex in 1877 and 1880 (66).  However, after 
the discovery of insulin and the resultant introduction of insulin therapy, these 
observations were largely ignored and diabetes was treated as a single disorder.  
 Attention finally returned to the classifications first introduced by Bouchardat 
and Lancereauex in the twentieth century.   Himsworth, in 1935, proposed an arbitrary 
classification, made by age at the onset of diabetes, could distinguish between 
different underlying pathophysiologies.  Specifically, younger and thinner patients 
were more sensitive to insulin treatment then were their older, more obese 
counterparts.  In the 1950s type 1 and type 2 diabetes were finally recognized as the 
distinct disorders that Himsworth had described by demonstrating that serum from 
type 1 diabetics behaved as though it contained no insulin, in contrast to serum from 
type 2 diabetic subjects which behaved as if it did.  Thus, the current view of diabetes 
is as a syndrome of chronic nontransient hyperglycemia with or without glycosuria, 
most commonly of three origins termed type 1, type 2, and gestational diabetes (66). 
 Classification of the subtypes of diabetes is an ongoing process.  The World 
Health Organization released a report in 1999 on the diagnosis and classification of 
diabetes, in which it defines not only the aforementioned diabetes subtypes, but also 
defines impaired glucose regulation, an intermediate state of glucose regulation 
between normal and pathological (1).  Type 1 diabetes includes cases in which the 
primary insult is pancreatic beta-cell failure, with affected individuals prone to 
ketoacidosis.  Type 2 diabetes is the result of systemic insulin resistance and defects in 
insulin secretion leading to a relative insulin deficiency.  The latter form of diabetes 
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may go undiagnosed for many years since the level of hyperglycemia is not enough to 
produce the noticeable symptoms of diabetes.  Moreover, ketoacidosis is rare in this 
type of diabetes and insulin treatment is generally not required. Along with gestational 
diabetes, these distinct forms represent the three major classifications of diabetes.  
However, a stage in the development of type 2 diabetes has also been defined, that of 
impaired glucose regulation. 
 Impaired glucose regulation, although not a separate class of diabetes per se, 
represents a stage in the natural progression of type 2 diabetes, including both 
impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), two distinct 
forms of disordered glucose metabolism, the former during fasting conditions and the 
latter post-prandially.  In addition, IGT is often associated with the metabolic 
syndrome which is a cluster of disorders including hypertension, central obesity and 
dyslipidemia with or without hyperglycemia.  Insulin resistance appears to be a 
common factor in the syndrome, although the mechanisms for this resistance remain 
to be elucidated.   
 The metabolic syndrome includes compensatory hyperinsulinemia concurrent 
with transient postprandial hyperglycemia or subclinical fasting hyperglycemia.  This 
hyperinsulinemia is the result of the bodys attempt to overcome this peripheral 
insulin resistance.  Furthermore, features of the metabolic syndrome can be present for 
up to a decade prior to the development of glycemic disorders, and are associated with 
cardiovascular disease risk.  Individuals with the metabolic syndrome are at high risk 
of future diabetes (1), leading to the term prediabetes (19).  Following the 
development of overt diabetes plasma insulin will decline to near normal values 
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despite the maintenance of fasting hyperglycemia (28).  In severely diabetic 
individuals, those with plasma glucose exceeding 10-11 mM, insolinopenia will 
develop.   Therefore, the prediabetic state itself has been shown to be associated with 
increased cardiovascular disease risk, and has become a point of interest in the 
chronology of vascular dysfunction associated with type 2 diabetes.   
 
2.2 Epidemiology of Type 2 Diabetes 
Diabetes mellitus accounted for more than 193,000 deaths in the US in 
1997, and this may be an underestimation of diabetes-related mortality, as many 
deaths related to diabetic complications are attributed to other causes, e.g. 
cardiovascular disease (80).  In the year 2000, diabetes affected approximately 151 
million worldwide, with a projected increase of 46% by the year 2010.  Of these 
individuals, 90% are type 2 diabetics.  In addition, at least 200 million people 
worldwide have some degree of impaired glucose tolerance, and an estimated 40% 
of these individuals will progress to overt diabetes within 5-10 years (127).  In the 
US alone, 15 million suffer from type 2 diabetes, with an estimated 20 million more 
suffering from some degree of glucose intolerance (81).  Moreover, the prevalence 
of type 2 diabetes among the youth of the US is increasing.  For example, Pinhas-
Hamiel and colleagues (85) reported a 12% increase in the diagnosis of type 2 
diabetes among new diabetes diagnoses in patients aged 10-19 between 1992-1994.  
This increase in type 2 diabetes among our nations younth appears to parallel the 
national increase in obesity in children (107). 
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The presence of diabetes increases cardiovascular disease risk 2 to 6-fold 
over that in normal healthy adults (8, 10, 43, 54), with 40% of type 2 diabetics 
presenting with concurrent hypertension (114).  Moreover, patients with the 
metabolic syndrome, individuals with at least three of the following conditions, 
abdominal obesity, hypertension, atherogenic dyslipidemia, and high fasting 
glucose (58) are at a significantly greater risk of cardiovascular disease than normal 
healthy adults, and an estimated 40% of these patients will progress to overt type 2 
diabetes within 5-10 years (127). 
Cardiovascular complications are now the leading cause of the morbidity 
and mortality associated with diabetes (4).  The macrovascular complications of 
diabetes result in atherosclerotic disease, hypertension, increased risk of myocardial 
infarction and stroke (4, 43). Dysfunction of the microvasculature resulting from 
diabetes is responsible for a number of co-morbidities associated with prolonged 
diabetes, e.g. retinopathy, neuropathy, and nephropathy.  As a result, diabetes has 
become the leading cause of blindness in adults aged 20-74 (31), lower limb 
amputations, and accounts for 40% of all new cases of end stage renal failure (91).  
All of these complications pose a significant burden on the health care system with 
the cost of diabetes-related health care reaching $105 billion dollars annually (80). 
It is becoming clear that the cardiovascular complications normally 
associated with advanced diabetes are beginning prior to the diagnosis of overt type 
2 diabetes and are related to long term impaired glucose tolerance and 
hyperinsulinemia related to a prediabetic dysfunction in glucose metabolism (45).  
Insulin resistance in the absence of frank diabetes is itself a significant risk factor 
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for cardiovascular disease.  For example, the metabolic syndrome is associated with 
more than a 2-fold increase in the risk of microvascular disease and myocardial 
infarction (8, 10, 43, 54).  Hyperinsulinemia itself could be the cause of 
hypertension seen prior to frank diabetes.  Elevated plasma insulin concentrations 
can alter both the renal sodium reabsorption leading to an increase in vascular 
volume, and can also increase sympathetic nerve activity (81).  In addition, 
hyperinsulinemia has been implicated in the development of hypertension by 
activition of ion channels, increasing cellular calcium concentrations and 
stimulating production of growth factors (23).  As a result, attention is now being 
given to vascular function not only after the development of diabetes but also 
during prediabetes.   
 
2.3 Insulin Action 
 Insulin acts as an anabolic hormone, stimulating protein synthesis and the 
uptake of glucose, triglycerides, and amino acids into tissues, but also acts on 
vascular tissues as a vasodilator via nitric oxide and has anticoagulent effects on the 
vascular endothelium.  The vascular effects of euglycemic insulin infusion are time 
and dose dependent.  Insulin infusion first induces an increase in glucose extraction 
that lasts approximately 60 minutes.  However, if insulin infusion is continued, 
glucose extraction plateaus, whereas blood flow increases continuously in response 
to insulin infusion. The flow response to insulin infusion is dependent on the 
particular vascular bed examined.  Muscles composed primarily of highly-oxidative 
type I muscle fibers display a greater increase in blood flow to insulin infusion than 
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do muscles composed primarily of type IIa or IIb fibers, and are therefore 
considered insulin sensitive (123). 
 Insulin resistant non-diabetic subjects are at a higher risk of cardiovascular 
disease than are subjects with impaired beta cell function but normal insulin 
sensitivity (44).  This relationship between insulin resistance and macroangiopathy 
could be responsible for the significant cardiovascular disease often present at the 
time of diagnosis in type 2 diabetic patients.  A reduction in insulin signaling 
through particular transduction pathways will result in an impaired peripheral 
action, whereas the elevated circulating insulin concentrations may also result in an 
enhanced hormonal effect (25).  The net effect of these alterations on the 
vasculature may be a decrease in nitric oxide synthase activity in insulin resistant 
states and a subsequent loss of the anti-artherogenic effects of NO (2), as well as an 
enhanced production of the procoagulent, plasminogen activator inhibitor 1 (PAI-1) 
(16). 
 Insulin also elevates muscle sympathetic nerve activity that induces 
vasoconstriction via stimulation of the α-adrenergic receptors.  In addition, insulin 
will stimulate the secretion of endothelin-1 from the vascular endothelium, a potent 
vasoconstrictor (104).  Thus, insulin has a dual effect on the vasculature, 
vasodilation via increases in NO and the Na+-K+ ATPase and vasoconstriction via 
sympathetic nerve activity and endothelin-1 production.  At normal physiological 
insulin concentrations the net effect of insulin is vasodilation in skeletal muscle 
(50).  Clearly, alterations in tissue sensitivity to insulin or insulin availability in the 
prediabetic state could have dramatic effects on vascular structure and function 
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even before true diabetes is manifest. The two major defects in type 2 diabetes are 
impaired insulin sensitivity and secretion.  Impaired secretion may be biphasic, 
such that IGT induces an increased insulin secretion and subsequent 
hyperinsulinemia and increased circulating preproinsulin and c-peptide, all of 
which may affect vascular function independent of the hyperglycemia that will later 
accompany frank diabetes. 
 Insulins vasodilator action is blunted in diabetic and insulin resistant states 
independent of frank endothelial dysfunction (60). The diabetic state appears to 
predispose an individual to endothelial dysfunction.  The insulin resistance that 
precedes frank diabetes in type 2 individuals is associated with impaired insulin-
induced dilation.  However, kinetic studies of insulin action point to a rate-limiting 
step in the pathway that precedes insulin binding to the receptor, and may reflect a 
defect in transendothelial transport (104).  Impaired endothelium-dependent 
dilation in metabolically important vascular beds such as skeletal muscle and 
adipose tissue may be both cause and consequence of insulin-resistance (60). 
However, at present, endothelium-dependent vasodilation has not been studied 
adequately in Type 2 diabetes and prediabetes (104) and as a result, a better 
description of the progression of cardiovascular complications prior to frank 
diabetes is warranted. 
 
2.4. Blood Flow and Glucose Uptake 
The skeletal muscle is the largest sink for plasma glucose with 
approximately 50-60% of an oral glucose load being cleared by the skeletal muscle.  
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Predominately high-oxidative skeletal muscle has a higher rate of glucose uptake 
than low-oxidative glycolytic skeletal muscle, and substrate delivery to the tissue, 
e.g. blood flow to the muscle, is a primary determinant of the quantity of glucose 
cleared from the blood.  Although non-insulin mediated skeletal muscle glucose 
uptake accounts for approximately 75-85% of the total rate of glucose utilization, 
under conditions of elevated plasma glucose, as occurs post-prandially, greater than 
80% of this additional glucose is cleared from the plasma via an insulin-dependent 
mechanism (121).  Within a given skeletal muscle, rates of glucose uptake differ in 
a fiber type specific manner, with high rates of 2-deoxyglucose uptake being found 
in the deep portion of the gastrocnemius muscle, consisting of high-oxidative 
muscle fibers and a low rate of glucose uptake in both the middle and superficial 
portions which consist primarily of low-oxidative glycolytic muscle fibers (47).  
This difference in glucose utilization may be influenced by the distribution of blood 
within the muscle. 
The microvasculature is the network of arteries in the vascular tree that are 
responsible for the distribution of blood flow between and within tissues, as well as 
for the majority of systemic vascular resistance.  During resting conditions, 
approximately half of the skeletal muscle is blood-perfused, with the other half of 
the capillaries plasma filled (96). Capillary perfusion is determined by the pressure 
gradient across the capillary bed, which is itself a function of blood flow and 
precapillary resistance determined at the level of the first, second, and third-order 
arterioles (39, 68, 108).  Vascular tone in the resistance arterioles will determine 
which vascular beds are perfused with blood.  In vivo, insulin stimulated glucose 
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uptake is accompanied by an increase in blood flow to the splanchnic and other 
peripheral circulations (121), with insulin playing an active role in this increase in 
glucose utilization by inducing peripheral vasodilation (8, 86, 121).   
Baron (8) reported an attenuated whole leg blood flow response to systemic 
insulin infusion in insulin resistant and type 2 diabetic individuals resulting in a 
30% reduction in glucose utilization.  In addition to reductions in total blood flow, 
alterations in the distribution of flow between areas of primarily high-oxidative or 
low-oxidative glycolytic skeletal muscle may affect glucose utilization.   Such 
differential changes in microvascular reactivity from predominately high-oxidative 
or low-oxidative glycolytic locomotor skeletal muscles in aged Fisher rats (77) 
have previously been described.  It is possible that similar changes in reactivity 
between high-oxidative or low-oxidative glycolytic muscles may also exist in type 
2 diabetic animals.  However, no such comparisons have been made in insulin 
resistance and diabetes.  If the resistance arterioles of high-oxidative or low-
oxidative glycolytic skeletal muscles are also differentially affected by 
hyperinsulinemia, insulin resistance and hyperglycemia, as occurs with aging, then 
these alterations in vascular function may alter the normal distribution of the blood 
flow between glycolytic or oxidative fibers within or between skeletal muscles and 
result in diminished glucose clearance.   
Total peripheral resistance may also be affected by altered reactivity of 
specific skeletal muscle vascular beds.  Peripheral resistance is determined, at least 
in part, by endothelial NO production via its modulation of vasoconstrictor tone at 
the level of the resistance arterioles (42).   Even at rest, the rat hindlimb skeletal 
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muscle receives approximate 15-20% of the total cardiac output and that fraction 
increases to approximately 90% with exercise (42).  Alterations in the balance of 
vasoconstrictor and vasodilator function in skeletal muscle arterioles in the insulin 
resistant state or in diabetes could increase total peripheral vascular resistance and 
contribute to the hypertension often associated with prediabetes and type 2 
diabetes. 
 
2.5 Proposed Cellular Mechanisms of Vascular Complications 
Intracellular hyperglycemia leads to increases in blood flow and vascular 
permeability due to changes in the balance between the activities of 
vasoconstrictors and vasodilators and alterations in matrix components (13).  
Insulin resistance leads to pathway specific alterations such that the vasodilator 
actions of insulin are lost through a specific dysfunction of the 
phosphyatidylinositol-3-OH pathway.  However, a concurrent increase in the 
insulin-induced activation of the mitogen-activated protein kinase pathway results 
in an increase in vascular smooth muscle proliferation and a pro-coagulent state 
(13). Four major hypotheses have emerged to explain vascular dysfunction in 
diabetes, including increased flux through the polyol pathway, increased advanced 
glycated endproduct (AGE) formation, increased protein kinase C activation 
(PKC), and increased hexosamine pathway flux (13). 
 Hyperglycemia itself can have injurious effects on tissues, particularly on 
those that are not dependent on insulin for glucose uptake.  Tissues lacking 
sensitivity to insulin action are unable to downregulate glucose entry in response to 
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increases in extracellular concentrations.  Transient postprandial hyperglycemic 
episodes in prediabetic individuals may contribute to the early onset of diabetic 
complications in type 2 diabetic individuals.  These short term elevations in 
glycemia have been shown to increase flux through alternate biochemical pathways 
of glucose disposal such as the polyol, hexosamine, and diacylglycerol pathways 
resulting in an increase in oxidative stress.  Further, a sustained increase in blood 
glucose concentrations will additionally have a cumulative effect on long-lived 
macromolecules, e.g. the non-enzymatic glycosylation of extracellular matrix 
proteins (100).  
 The polyol pathway converts glucose to sorbitol via the enzyme aldose 
reductase (AR) when glucose is in excess of glycolytic needs.  A consequence of an 
increased flux through the polyol pathway is the generation of an excess of NADH 
which occurs when sorbitol is converted to fructose via sorbitol dehydrogenase.  
The resultant increase in the NADH to NAD+ ratio mimics ischemic changes and 
has been termed hyperglycemic pseudohypoxia or reductive stress(103).  
Moreover, the increase in NADH drives the generation of glyceraldehydes-3-
phosphate (GA-3-P), a precursor to the AGE forming methylglyoxal (MGO) and 
diacylglycerol (DAG), an endogenous activator of PKC via glyceraldehydes-3-
phosphate dehydrogenase (GAPDH).  This increase in glucose flux through the 
polyol pathway is accompanied by a depletion of myoinositol, altered 
phosphoinositide turnover, a decrease in intracellular calcium concentrations, and a 
decrease in the activity of the Na+-K+ ATPase, all of which may contribute to 
cardiovascular complications (103).  Alterations in the redox potential may be 
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responsible for an increase in free radical generation, AGE accumulation, PKC 
activation, and hexosamine formation.   
 Hexosamine formation occurs when fructose-6-phosphate is converted to 
glucosamine-6-phosphate via glucosamine-fructose-amidotransferase (GFAT).  
Increased concentrations of hexosamines may mediate the vascular damage by 
hyperglycemia as well as induce insulin resistance, termed glucose toxicity.  
Increased hexosamine concentrations enhance PKC translocation, induce 
glycosylation, and can activate growth factors like TGF-β1 and PAI-1.  Moreover, 
they may inhibit PKC activated GLUT4 translocation, thereby reducing glucose 
transport and utilization. 
 The formation of advanced glycated endproducts (AGEs), which is 
correlated with the level of glycemic control, can also alter the structure and 
function of membrane proteins.  AGEs are formed when reducing sugars react non-
enzymatically with amino groups of proteins.  Through a series of reactions, Schiff 
bases and Amadori products form AGEs.  This process, discovered in the 1900s, is 
termed the Maillard reaction.  AGE formation is catalyzed by transitional metals 
and is inhibited by reducing compounds (100).  Reactive intermediates form during 
the Maillard reaction and are implicated as a mechanism of diabetes induced 
damage.  The formation of these intermediates is accomplished by non-oxidative 
rearrangement and hydrolysis of Amadori products, examples of which are 3-
deoxyglucosone (3-DG) and methylglyoxal (MGO).  These products can be further 
modified into oxidative AGEs leading to carbonyl stress, which may be involved in 
the accelerated vascular damage seen in diabetes (100).  AGE-related damage to 
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vascular tissues may be more dependent on the rate of accumulation than the 
concentration of AGE, as suggested by a lower concentration of AGE in insulin-
dependent diabetic subjects despite microvascular complications when compared to 
healthy older non-diabetic patients (100).    
 AGEs were once believed to simply tag senescent proteins for degradation, 
but recently it has been discovered that AGEs activate signaling pathways that lead 
to the synthesis and release of growth factors and cytokines that may both initiate 
tissue turnover and repair, but may also contribute to diabetic vascular 
complications (111, Bierhaus, 1998 #185).  For example, glycated membrane 
proteins are more highly cross-linked resulting in a decrease in solubility and 
proteolytic turnover (30).   
 AGE modified proteins on the ECM will decrease membrane elasticity, 
increase wall thickness, and enhance rigidity, and can result in a reduction in 
luminal diameter (9).  AGEs on ECM proteins can interfere with endothelial 
function in a number of ways.  AGEs inhibit normal network formation in type IV 
collagen, decrease proteoglycan binding by vitronectin and laminin, quench NO 
during passage from endothelium to smooth muscle layer, bind and activate cell 
surface receptors, increase membrane permeability, and induce tumor necrosis 
factor-alpha (TNF-α).  TNF-α may itself induce insulin resistance in muscle and 
adipose tissues by impairing autophosphorylation of insulin-receptor and insulin 
receptor substrate.  In addition, AGEs also induce the expression of endothelin-1, a 
potent endothelium-derived vasoconstrictor (9). 
 Diabetic vascular disease also appears to result in an unregulated process of 
  
19
tissue remodeling sustained by an abnormal expression of factors regulating tissue 
homeostasis of both resident and non-resident vascular cells (25).  During normal 
vascular remodeling, adhesion molecules provide communication between the 
lumen and vessel wall in both directions.  The endothelial barrier protects against 
passage of macromolecules from the lumen to the interstitium and comes into 
contact with circulating elements such as leuckocytes.  Contractile elements 
respond to perfusion pressure and oxygen demand to establish vessel tone, and 
endothelial cell interactions with adhesion molecules and non-resident cells 
establish balance between pro- and anticoagulent states to prevent thrombus 
formation.  With diabetes, vascular remodeling is perturbed.  The cell-matrix 
composition of the vascular wall is altered such that there is an enhanced deposition 
of the vascular basement membrane resulting from increased synthesis(38, 88) and 
decreased degradation of matrix proteins (79, 90).  However, changes in the cell 
compartment are more complex.   
 Vascular cellularity may either increase due to a proliferation of vascular 
smooth muscle cells or the inflow of non-resident cells, or decrease as the result of 
a decrease in proliferation or an increase in apoptosis.  Moreover, cell-to-cell, and 
cell-to-matrix communication is disturbed.  An abnormal pattern of contact 
molecule expression has been observed in diabetic vascular tissues.  Increases in 
integrin expression have been reported leading to an upregulation of fibronectin 
and enhanced endothelial cell-matrix attachments(92).  Similarly, an abnormal 
pattern of adhesion molecules leads to increased leukocyte rolling and adhesion, 
which allows for enhanced deposition of non-resident macromolecules into the 
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vessel wall (74).   
 Contributing to this increase in macromolecule deposition is a loss of the 
barrier function of the vascular endothelium.  Barrier function loss is the result of 
basement membrane thickening, hemodynamic changes, endothelial dysfunction, 
and alterations in the plasma.  Functional alterations can result from these changes 
in vessel structure.  Basement membrane thickening is a hallmark of both type 1 
and type 2 diabetes and is positively correlated with disease duration (30).  
Hyperglycemia, hyperinsulinemia and cytokines have been shown to result in an 
increase in the mRNA expression for laminin, fibronectin and type IV collagen.  
Yu et al. (124) reported an increase in type IV collagen, fibronectin and laminin 
following 2 weeks of streptozotocin-induced Type 1 diabetes in cremaster and 
femoral arteries.  Increased shear stress and pressure have also been shown to 
increase production of these membrane components and may be present 
concomitantly in some diabetic patients.  Increases in these extracellular matrix 
proteins could reduce vascular elasticity, alter membrane permeability, interfere 
with normal cell-matrix interactions, and cause the endothelium to lose its 
antithrombotic, profibrinolytic effect (30, Stehouwer, 1997 #191), all of which may 
contribute to a stiffer, less compliant vessel. 
 
2.6 Complications of Diabetes 
 Diabetic vascular complications affect a number of tissues beds and result 
in characteristic features unique to the tissues involved.  Moreover, the incidence of 
these complications varies among tissue beds and the commonly affected tissues 
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appear to vary by the type of diabetes.  For example, among type I diabetics 
approximately 30% will develop nephropathy, whereas 80-90% will develop some 
degree of retinopathy (25).  Of the 90% of diabetics who will develop background 
retinopathy, 8-26% will develop proliferative retinopathy leading to vessel 
hemorrhages, ischemia, and infarctions.  Both retinopathy and nephropathy are 
believed to be the result of dysfunction of the microvasculature leading to these 
organs.  However, among type 2 diabetics, macrovascular disease is more common 
than among type 1 diabetic patients, and is manifest as a high incidence of 
hypertension in this population (25).  Complications may develop independent of 
one another, such that 17% and 25% of diabetics will present with cardiovascular 
disease or retinopathy alone, respectively.  However, in those patients with diabetic 
nephropathy, some degree of cardiovascular disease and retinopathy is usually 
present as well (25).  There also appears to be a time dependence related to the 
development of these complications.  For example, in type 2 diabetics, 
macroangiopathy is often present at the time of diagnosis whereas microangiopathy 
is believed to develop as a late consequence of the disease.  Moreover, the risk of 
retinopathy increases linearly with disease duration while the risk of nephropathy 
peaks at 15 years of disease and then declines (25).  Cardiovascular complications 
of overt diabetes have been extensively studied in type 1 diabetic patients and 
animal models of the disease.  Although late complications of type 1 and type 2 
diabetes vary, similar alterations in vascular structure and function to those seen in 
type 1 diabetes may contribute to vascular dysfunction in type 2 diabetes and may 
become manifest prior to the onset of frank diabetes. 
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 Following development of overt diabetes, structural and functional changes 
in the vasculature occur in a tissue-dependent manner.  The majority of 
investigations examined the effects of type I diabetes on the morphology and 
vasoreactivity of both macro- and microvessels, and the results may not be 
consistent with changes found with type 2 diabetes.  The hemodynamic hypothesis 
put forth by Parving et al. (83) attempts to define the sequelae of changes leading to 
diabetic vascular complications.  This hypothesis implicates hyperglycemia-
mediated increases in capillary perfusion pressure in the overproduction of 
basement membrane components as well as shear stress induced damage to the 
endothelium, leading to a stiffening of the vessels and altered endothelial cell 
function that results in a reduction in the maximal hyperemic response in diabetic 
vessels.  This is an attractive hypothesis that has been supported in the type 1 
diabetes literature, however increased capillary pressure is not a consequence of the 
type 2 diabetic state, and thus, does not appear to describe the progression of the 
disease in type 2 diabetes (115).  However, there is evidence that the ultimate result 
of type 2 diabetes on the vasculature does indeed appear to be a reduction in the 
maximal hyperemic response, consistent with the findings in type 1 diabetes. 
 Less is known about possible vascular alterations induced by type 2 
diabetes and the time course of these putative changes.  Type 2 diabetes related 
complications result from a variety of hormonal and metabolic derangements.  
Hyperinsulinemia, hyperglycemia and insulin resistance may coexist and contribute 
to vascular dysfunction.  In addition to the multiple abnormalities that exist in type 
2 diabetes, the progression of the disease is slow and often silent, resulting in long 
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periods of impaired glucose tolerance caused by a history of insulin resistance.  
Structural and functional alterations in the microvasculature may already be present 
during prediabetes.  Microalbuminuria seen during prediabetes is suggestive of 
structural alterations in the basement membrane and endothelium, leading to 
increased permeability (25, 120).  However, little information is available regarding 
structural alterations during this phase in the development of diabetes.  An increase 
in muscle capillarization has been reported in rats exposed to 1 week of 
hyperinsulinemia and is most pronounced in low-oxidative glycolytic muscles of 
IGT patients (121).  This increase in capillary density may be a transient adaptation 
to inadequate substrate availability, as capillary rarefaction has been reported to be 
the ultimate consequence of the diabetic state (120).  Similarly, little functional 
data is available from prediabetic animals and patients.  Due to methodological 
limitations, the information available is often obtained from large vessels and 
vascular beds that may not be representative of other areas, such as the cutaneous 
circulation (120).  In normotensive type 2 diabetics, capillary pressures are normal 
despite an early profound decrease in cutaneous vasodilator capacity present at 
diagnosis (115).  Few estimates of microvascular dysfunction are available in type 
2 diabetic patients.  In contrast to studies in type 1 diabetes, capillary pressure and 
filtration are normal in type 2 diabetics despite a profound decrease in maximal 
microvascular blood flow.  This decrease in microvascular blood flow has been 
shown at the time of diagnosis and is equivalent to that seen in type 1 patients after 
18 years of disease (113).  It is presently unknown whether there is an enhanced 
vasoconstrictor or diminished vasodilator response in resistance vessels of type 2 
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diabetics.  Such dysfunction could contribute to the chronic hypertension seen in 
type 2 diabetic patients. 
 
2.7 Vascular Dysfunction in Type 2 Diabetes 
 The most profound abnormality in type 2 diabetes appears to be a decrease 
in the maximal hyperemic response, measured in the cutaneous circulation, which 
is present at diagnosis.  A decreased hyperemic response to local heating has been 
reported in the cutaneous circulation of the forearm in patients with impaired 
fasting glucose (IFG), and this response was correlated to insulin concentrations 
but not to glycemia (55).  Moreover, reduced flow-induced vasodilation has been 
found in first-degree relatives of type 2 diabetics (7), indicating that the alterations 
in vascular function are present not only as a precursor to diabetes but the result of 
an inherited vascular dysfunction.  Hyperglycemic non-diabetic patients display a 
decreased vasodilator capacity that is correlated with insulin resistance. Moreover, 
Caballero et al. (15) and Brett et al. (2000)(12) found decreased acetylcholine 
(ACh) and sodium nitroprusside (SNP) induced vasodilations in the cutaneous 
circulation of type 2 diabetic patients.  Vischer et al. (118) also found a diminished 
response in forearm blood flow to ACh in insulin resistant and type 2 diabetic 
individuals, but found no change in the SNP response. 
The use of animal models allows for the examination of changes in vascular 
responsiveness in highly specific vascular beds.  Although endothelial dysfunction 
and impaired vasodilator capacity have been documented in the skeletal muscle 
vasculature of diabetic rats and insulin resistant humans (8, 33, 37, 110, 112), this 
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finding has been inconsistent, as others have reported increased responsiveness to 
endothelium-dependent vasodilators in obese Zucker rats (3) and skeletal muscle 
arterioles of normoglycemic rats exposed to acute hyperglycemia (61). 
In addition to the specificity of the vasculature studied, the use of animal 
models has allowed the examination of changes in vascular responsiveness as a 
function of duration of insulin resistance.  Cox and Kikta (1992) (22) examined 
changes in the function of the thoracic aorta in obese Zucker rats across the lifespan 
and found increases in vasoconstrictor responsiveness that diminished with 
advancing age.  Futhermore, ACh-induced vasodilation was enhanced in the 
youngest obese rats with no change in SNP-induced dilation at any age. Similar 
results were reported by Sexl et al. (99), who found relaxation to ACh and a 
calcium ionophore to be increased in the aorta of obese rats compared to their age-
matched controls in young (12 week) obese Zucker rats, but not at any other age 
(24, 36, and 52 weeks).  By examining the reactivity of the aorta from obese rats 
these investigators have been able to document changes in vessel function as the 
insulin resistant state worsens.  However, no such examination has been made in 
the microcirculation. 
 In conjunction with altered vasodilator function, enhanced vasoconstrictor 
responsiveness could also play a role in diabetic microangiopathy.  Previous 
investigations into the vasoconstrictor responsiveness of arterioles from diabetic 
and insulin resistant humans and animals have produced inconsistent results.  
Constriction to norepinephrine (NE) has been shown to be either unchanged (97) in 
human subcutaneous fat arterioles and type 1 diabetic arterioles (70) or increased in 
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gracilis muscle arterioles from 13-15 week old obese Zucker rats (OZR) (105).  
Constriction to other pharmacological agonists have been similarly variant, with 
either increased (70), unchanged (105), or decreased (122) constriction to 
angiotensin II and endothelin-1 being reported.  Moreover, myogenic constriction 
has been shown to be both increased in gracilis muscle arterioles from 
streptozotocin-induced diabetic rats (116) as well as OZR rats (34) and decreased in 
subcutaneous adipose tissue arterioles from type 2 diabetic patients (97) and 
streptozotocin induced diabetic rats (48). 
In addition to altered reactivity, the structure of the microvasculature may 
also be deranged by insulin resistance and diabetes.  Altered permeability and 
basement membrane thickening have been well documented in both the renal and 
retinal circulations.  Hyperinsulinemia has been implicated as stimuli for vascular 
remodeling (103).  Previous investigators have found changes in vessel wall 
structural characteristics in type 2 diabetic human adipose arterioles (87, 97), type 2 
diabetic coronary arterioles (125), and type 1 diabetic rat mesenteric arterioles (93).  
In these studies, increases in medial wall thickness, cross-sectional area, and wall-
to-lumen ratio have been reported and are consistent with hypertrophic remodeling.  
However, others have reported decreases in medial wall thickness, wall-to-lumen 
ratio, and decreased distensibility in gracilis muscle arterioles from obese Zucker 
rats (34).  Lacking however is an examination of the structural adaptations of 
skeletal muscle arterioles during the progression of type 2 diabetes from insulin 
resistance to prolonged overt diabetes. 
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2.8 Hypotheses 
The specific aims of this study were therefore to test the hypotheses that 1) 
type 2 diabetes will enhance myogenic responsiveness of resistance arterioles 
isolated from muscles composed of different fiber types, 2) type 2 diabetes will 
increase the passive stiffness of these skeletal muscle resistance arterioles, 3) type 2 
diabetes will increase responsiveness of skeletal muscle resistance arterioles to 
vasoconstrictor agonists, 4) type 2 diabetes will attenuate skeletal muscle arteriolar 
responsiveness to either endothelium-dependent or endothelium-independent 
vasodilator stimuli, and 5) that these changes will be present during the prediabetic 
state as well as during acute and chronic type 2 diabetes. 
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CHAPTER III 
 
 
VASODILATOR DYSFUNCTION IN LOCOMOTOR SKELETAL 
MUSCLE ARTERIOLES FROM ZUCKER DIABETIC FATTY RATS IS 
DEPENDENT ON DISEASE PROGRESSION AND FIBER TYPE 
 
3.1 Overview 
 Endothelial dysfunction in skeletal muscle arterioles could impact both 
peripheral insulin resistance and hypertension observed in type 2 diabetes.  The 
purpose was to determine if endothelial dysfunction is present in arterioles isolated 
from high-oxidative and low-oxidative glycolytic skeletal muscles during 
prediabetes as well as acute and chronic diabetes, and to determine if this 
dysfunction precedes elevations in arterial pressure.  Zucker Diabetic Fatty (ZDF) 
rats and lean age-matched controls were studied at 7 (prediabetes), 13 (acute 
diabetes) and 20 (chronic diabetes) weeks of age.  Following measurement of 
arterial pressure, vasodilator responsiveness to acetylcholine (ACh), and 
intraluminal flow were examined in isolated arterioles from the soleus and white 
gastrocnemius muscles.  Moreover, the contribution of nitric oxide (NO) in ACh-
induced vasodilation was assessed.  Flow-induced vasodilation was decreased in 
the high-oxidative muscle arterioles during acute diabetes, and this was coincident 
with the emergence of elevated arterial pressure.  During chronic diabetes, 
vasodilation to ACh and flow were reduced in soleus muscle arterioles.  The 
reduced vasodilation to ACh was the result of a loss of NO. Although the 
vasodilatory capacity of low-oxidative glycolytic skeletal muscle arterioles was not 
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diminished at any timepoint, the contribution of NO to ACh-induced dilation was 
lost in the prediabetic and acute diabetic rats. The data demonstrate that although 
endothelial dysfunction does not become manifest in low-oxidative glycolytic 
skeletal muscle arterioles, alterations in the signaling mechanisms to achieve that 
vasodilation occur in the prediabetic state.  Moreover, endothelial dysfunction is a 
consequence of the diabetic state in high-oxidative skeletal muscle arterioles. 
 
3.2 Introduction  
Cardiovascular complications are now the leading cause of the morbidity 
and mortality associated with diabetes (4), and it appears that these complications 
begin years before the onset of overt diabetes and are related to long term impaired 
glucose tolerance and hyperinsulinemia (45).  The skeletal muscle and its 
vasculature may have profound implications for the development and progression 
of insulin resistance and hypertension associated with prediabetes and frank type 2 
diabetes.   A diminished vasodilator capacity of the skeletal muscle resistance 
vasculature could affect the magnitude and distribution of cardiac output, glucose 
uptake, as well as total peripheral resistance.  Furthermore, if resistance arterioles 
from high-oxidative or low-oxidative glycolytic skeletal muscles are differentially 
affected by hyperinsulinemia, insulin resistance, or hyperglycemia, then these 
alterations could function to change the normal distribution of the blood flow 
between glycolytic and oxidative fibers within or between skeletal muscles, and 
consequently result in diminished glucose clearance.   
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Inconsistencies have been reported in the literature regarding vasodilator 
function in insulin resistance, hyperglycemia, and type 2 diabetes.  Although 
endothelial dysfunction and impaired vasodilator capacity have been shown in the 
vasculature of diabetic rats and insulin resistant humans by some investigators (8, 
33, 37, 110, 112), others have reported enhanced responsiveness to endothelium-
dependent and independent vasodilators in obese Zucker rats  (3), (6) and skeletal 
muscle arterioles of normoglycemic rats exposed to acute hyperglycemia (61).  
Lacking, however, is an examination of the changes in microvascular vasodilator 
function during the progression of type 2 diabetes from prediabetes through the 
chronic overt diabetic state.   
 Therefore, the purpose of the present study was 1) to determine whether 
alterations in the vasodilator capacity of skeletal muscle arterioles exist during the 
natural progression of type 2 diabetes in a rat model, and 2) to determine whether 
the putative effect differentially occurs in arterioles from skeletal muscles 
composed of different fiber types and oxidative capacities.  The Zucker diabetic 
fatty (ZDF) rat was chosen because it has been shown to initially develop 
peripheral insulin resistance and then, frank type 2 diabetes over a predictable age 
range (27, 56).  Moreover, these rats develop many of the same conditions as 
prediabetes and type 2 diabetes in humans, such as obesity (11), hypertension (56, 
126), and abnormal blood lipid profiles (11, 27, 101, 102), making it a clinically 
relevant model.    
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3.3 Materials and Methods 
 Male ZDF rats were obtained from Charles Rivers Laboratories / Genetic 
Models Inc.  Diabetic (ZDF:fa/fa) and lean (ZDF: +/?) age-matched controls were 
studied at 7, 13, and 20 weeks of age to represent prediabetes and acute (1 week) 
and chronic (8 weeks) diabetes.  Animals were housed separately and allowed free 
access to Purina 5008 diet and water.  Animals were housed in a temperature 
controlled (23 ± 2 ºC) room with a 12:12 light-dark cycle.  All animal procedures 
were approved by the Texas A&M University Laboratory Animal Care Committee 
and complied by the guidelines of the National Research Council Guide for the 
Care and Use of Laboratory Animals (Washington DC: National Academy Press, 
Revised 1996).  
 
3.3.1 Animal Procedures  
Rats were anesthetized with sodium pentobarbital (65 mg/kg) via i.p. 
injection.  A polyurethane (Braintree Scientific, Micro-renathane; ID 0.36 mm, OD 
0.84 mm) catheter filled with heparinized saline was inserted into the caudal artery 
via a 1 cm incision in the ventral surface of the tail.  Electronically averaged mean 
arterial pressure was recorded while the rat was maintained under anesthesia.  
Following blood pressure measurement, blood was collected via cardiac puncture 
for assessment of plasma glucose and insulin content, and the heart removed.  
Whole heart and left and right ventricular masses were recorded.  The 
gastrocnemius-plantaris-soleus muscle complex was then carefully excised from 
each leg. 
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3.3.2 Microvessel Preparation  
Following excision, the gastrocnemius-plantaris-soleus muscle complex 
was placed in cold (4º C) physiological saline solution (PSS) that contained 145.0 
mM NaCl, 4.7 mM KCl, 2.0 mM CaCl2, 1.17 mM MgSO4, 1.2 mM NaH2PO4, 5.0 
mM glucose, 2.0 mM pyruvate, 0.02 mM EDTA, 3.0 mM MOPS buffer and 1 
g/100 ml BSA, pH 7.4.  Gastrocnemius and soleus muscle first-order (1A) 
arterioles were isolated with the aid of a dissecting microscope (Olympus SVH10) 
as previously described (71, 76).  In the soleus muscle, 1A arterioles were defined 
as the first arterial branch after the feed artery entered the muscle.  In the 
gastrocnemius muscle, 1A arterioles were defined as the first branch off the feed 
artery that runs over the superficial portion of the muscle.  The arterioles (length, 
0.5 - 1.0 mm; inner diameter, soleus: 31  163 µm, gastrocnemius: 53 -168 µm) 
were cleared of surrounding muscle fibers, removed from the muscle and placed in 
lucite chambers containing MOPS buffered PSS equilibrated to room air.  The 
arterioles were cannulated on both ends to micropipettes and secured with nylon 
suture.  After cannulation, the chambers were transferred to the stage of an inverted 
microscope (Olympus IX70) equipped with a video camera (Panasonic BP310), 
video caliper (Microcirculation Research Institute), and data acquisition system 
(MacLab/Macintosh) for recording of luminal diameter.  Arterioles were initially 
pressurized to 44 mmHg with two independent hydrostatic pressure reservoirs.  
Leaks were detected by pressurizing the vessel and then closing the reservoirs 
verifying that diameter remained constant.  Arterioles that exhibited leaks were 
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discarded.  Arterioles free of leaks were warmed to 37º C and allowed to develop 
initial spontaneous tone during a 30-60 min equilibration period.    
 
3.3.3 Experimental Design  
To determine whether vasodilator function of the endothelium and vascular 
smooth muscle is altered at different periods in the natural progression of type 2 
diabetes, vasodilator responses of 1A arterioles isolated from the superficial portion 
of the gastrocnemius and soleus muscles to increasing intraluminal flow, 
acetylcholine (ACh), and sodium nitroprusside (SNP) were measured.  Sensitivity 
of the arterioles to pharmacological agonists was assessed by calculating the IC50.  
In a second set of experiments, the contribution of nitric oxide synthase (NOS) and 
cyclooxygenase (COX) signaling pathways in ACh-induced vasodilation was 
assessed.  The ACh dose responses were repeated in the presence of the NOS 
inhibitor NG-nitro-L-arginine methyl ester (L-NAME) or the combined NOS and 
COX inhibitors L-NAME and indomethacin (INDO). 
 
3.3.4 Vasodilation to Intraluminal Flow 
 After a steady-state spontaneous tone developed, arterioles were exposed to 
graded increases in intraluminal flow in the absence of changes in intraluminal 
pressure.  This was accomplished by altering the heights of the independent fluid 
reservoirs in equal and opposite directions.  Diameter measurements were made in 
response to incremental increases in intraluminal flow of 3-50 nl/sec (77).   
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3.3.5 Vasodilation to Pharmacological Agonists 
 Concentration-response relations to the cumulative addition of ACh (10-9 to 
10-4) and SNP (10-10 to 10-4) were determined.  These vasodilators were chosen 
because they cause vasodilation by activation of endothelial pathways and direct 
activation of smooth muscle guanylate cyclase (donation of NO), respectively.  The 
vessels were allowed to equilibrate between successive dose responses and were 
discarded unless at least 20% baseline tone was achieved prior to addition of 
vasodilator agents.  Maximal intraluminal diameter was determined by allowing the 
vessels to equilibrate in calcium free PSS following active dose responses.  
 
3.3.6 Inhibitory Effects of NG-nitro-L-arginine Methyl Ester and Indomethacin 
 After establishing spontaneous tone of at least 20%, vasodilator responses 
to ACh were evaluated after an 30 min incubation with 10-5 M  L-NAME or the 
combination of 10-5 M L-NAME and 10-5 M INDO. 
 
3.3.7 Solutions and Stocks 
 Stock solutions of drugs were prepared in distilled water and frozen.  Fresh 
dilutions of these stocks were prepared daily.  All drugs were purchased from 
Sigma Chemical (St. Louis, MO). 
 
3.3.8 Data Presentation and Statistical Analysis 
 Vasodilator responses were recorded as actual diameters and expressed as a 
percentage of maximal relaxation according to the following formula: 
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relaxation (%) = (Ds  Db)/(Dm  Db) *100  
Where Dm is maximal inner diameter at 44 mmHg, Ds is the steady-state inner 
diameter recorded after addition of drug or increase in intraluminal flow, and Db is 
the initial baseline inner diameter before the first addition of drug or intraluminal 
flow.  The IC50 was calculated for ACh and SNP, and differences were assessed by 
one-way analysis of variance (ANOVA). Repeated measures ANOVA was used to 
determine differences between age-matched diabetic and control groups for all dose 
responses. Fisher protected least significant difference post hoc was used where 
appropriate.  For animal data, one-way ANOVA was used to determine significant 
differences between diabetic and age-matched controls. All data are presented as 
mean ± SE.  Significance was set at P ≤ 0.05.  
 
3.4 Results 
 Body mass was greater in the 7 week old prediabetic fatty rats (F7) than the 
age-matched lean (L7) rats.  There were no differences in body mass between 
groups at either 13 or 20 weeks of age.  Heart mass was higher (10.4%) in the 
prediabetic fatty (F7) group, however, the heart-to-body mass ratio was lower in 
the F7 rats compared to age-matched controls (Table 3.1).  With overt diabetes, (13 
and 20 weeks), heart mass was lower in the fatty rats (6.5% and 17%, respectively) 
and this difference persisted when expressed relative to body mass (Table 3.1).   
Soleus muscle mass and soleus-to-body mass ratio did not differ between the 
prediabetic rats and the lean age-matched controls (Table 3.1).  The absolute soleus 
muscle mass did not differ between lean and fatty rats during acute diabetes,  
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Table 3.1. Descriptive Characteristics of Prediabetic (7), Acute (13) and 
Chronically (20) Diabetic Fatty (F) and Lean (L) Age-Matched Control 
Zucker Diabetic Fatty Rats 
 
Weeks of Age 7 13 20 
Group 
(n) 
L 
(15) 
F 
(15) 
L 
(13) 
F 
(14) 
L 
(13) 
F 
(11) 
Body mass (g) 201 ± 4 256 ± 5* 358 ± 4 377 ± 14 435 ± 5 410 ± 14 
Soleus muscle 
mass (mg) 109 ± 6 121 ± 6 194 ± 6 175 ± 7 227 ± 5 165 ± 9
* 
Soleus-to-body 
mass ratio (%) 
0.05 ± 
0.01 
0.05 ± 
0.01 
0.05 ± 
0.01 
0.04 ± 
0.01* 
0.05 ± 
0.01 
0.04 ± 
0.01* 
Gastrocnemius 
muscle  
mass (g) 
0.99 ± 
0.07 
1.03 ± 
0.03 
1.88 ± 
0.02 
1.45 ± 
0.05* 
2.07 ± 
0.16 
1.35 ± 
0.10* 
Gastrocnemius-
to-body mass 
ratio (%) 
0.49 ± 
0.13 
0.40 ± 
0.04* 
0.53 ± 
0.03 
0.39 ± 
0.02* 
0.47 ± 
0.13 
0.33 ± 
0.08* 
Whole heart 
mass (g) 
0.70 ± 
0.01 
0.77 ± 
0.02* 
1.07 ± 
0.02 
1.00 ± 
0.03* 
1.29 ± 
0.03 
1.07 ± 
0.02* 
Heart-to-body 
mass ratio (%) 
0.35 ± 
0.01 
0.30 ± 
0.01* 
0.30 ± 
0.01 
0.27 ± 
0.01* 
0.30 ± 
0.01 
0.26 ± 
0.01* 
Left ventricle 
mass (mg) 540 ± 13 693 ± 15
* 810 ± 12 761 ± 22 993 ± 24 835 ± 17*
Right ventricle 
mass (mg) 129 ± 10 148 ± 7 218 ± 12 197 ± 12 231 ± 7 196 ± 7
* 
 
* Denotes significant difference from age-matched control, P ≤ 0.05, (n) is the 
number of animals 
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however, the soleus-to-body mass ratio was lower in the fatty rats compared to age-
matched controls.   Both absolute and relative soleus muscle mass were lower in 
the fatty rats compared to lean age-matched controls during chronic diabetes. 
 The absolute mass of the gastrocnemius muscle did not differ between the 
fatty and lean rats during prediabetes (Table 3.1), but the gastrocnemius muscle-to-
body mass ratio was lower in the prediabetic fatty rats compared to age-matched 
controls.  During acute diabetes, gastrocnemius muscle mass was reduced in the 
fatty (F13) rats when compared to the lean controls (L13) and these differences 
persisted when expressed relative to body mass.  Absolute and relative 
gastrocnemius muscle mass was reduced in the fatty (F20) rats compared to age-
matched lean (L20) rats (Table 3.1).  
Plasma glucose was higher in all fatty groups relative to age matched 
controls (Figure 3.1A).  Plasma insulin was higher in the prediabetic rats, but was 
lower than that in control animals with both acute and chronic diabetes (Figure 
3.1B).  MAP did not differ between the fatty and lean rats during prediabetes, but 
was significantly elevated with acute and chronic diabetes (Figure 3.1C).   
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Figure 3.1.  Difference from Mean Control Values for Plasma Glucose (A), Plasma Insulin (B) 
and Mean Arterial Pressure (C) of Prediabetic (7), Acutely (13) and Chronically 
(20) Diabetic Fatty (F) and Lean (L) Age-Matched Control Zucker Diabetic Fatty 
Rats 
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Maximal diameter of soleus muscle arterioles did not differ between the 
fatty and lean rats at any stage of diabetes.  Likewise, maximal diameter of the 
gastrocnemius muscle arterioles were similar between the fatty and lean rats at both 
7 and 13 weeks of age (Table 3.2).  However, with chronic diabetes, maximal 
diameter of gastrocnemius muscle arterioles from the fatty rats was lower 
compared to those from the age-matched controls.   
Spontaneous tone did not differ between the fatty and lean rats in either 
muscle at any point in the progression of the disease (Table 3.2).  Incubation with 
L-NAME increased tone in gastrocnemius muscle arterioles from both the lean and 
fatty rats at all three timepoints (Table 3.2).  The combination of L-NAME and 
INDO increased tone in all gastrocnemius arterioles except in gastrocnemius 
muscle arterioles from the chronically diabetic rats (Table 3.2).  Incubation of 
soleus muscle arterioles with L-NAME increased tone in both the lean and fatty 
rats at 7 weeks of age, as well as from arterioles isolated from the lean rats at 13 
weeks of age (Table 3.2).  No differences in soleus muscle arteriolar tone was seen 
between the chronically diabetic rats and their age-matched controls.  The 
combined L-NAME and INDO blockade did not alter tone in soleus muscle 
arterioles.   
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Table 3.2. Characteristics of First Order Arterioles from Soleus and White 
Gastrocnemius Muscles 
 
 Soleus Muscle 
Weeks of age 7 13 20 
Group L F L F L F 
Maximal 
diameter (µm) 90 ± 10 100 ± 5 117 ± 8 113 ± 10 126 ± 6 122 ± 2 
 Spontaneous tone (%) 
Flow 40 ± 5 46 ± 10 42 ± 4 44 ± 4 41 ± 6 40 ± 7 
ACh 55 ± 7 54 ± 5 51 ± 5 51 ± 5 49 ± 5 46 ± 7 
Pre-L-NAME 39 ± 5 49 ± 6 38 ± 3 41 ± 7 47 ± 6 41 ± 5 
L-NAME 66 ± 8 73 ± 5 59 ± 6 68 ± 7 60 ± 6 50 ± 8 
Pre-L-NAME 
+ INDO 62 ± 9 58 ± 6 53 ± 6 56 ± 5 52 ± 7 44 ± 7 
L-NAME +  
INDO 68 ± 8 72 ± 5 65 ± 8 72 ± 5 67 ± 6 45 ± 10 
 Gastrocnemius muscle 
Weeks of age 7 13 20 
Group L F L F L F 
Maximal 
diameter (µm) 96 ± 7 101 ± 3 126 ± 10 116 ± 4 130 ± 4 110 ± 7
* 
 Spontaneous tone (%) 
Flow 36 ± 4 37 ± 4 36 ± 3 33 ± 7 32 ± 4 33 ± 5 
ACh 37 ± 3 41 ± 4 47 ± 3 43 ± 5 34 ± 3 42 ± 5 
Pre-L-NAME 40 ± 6 29 ± 4 28 ±3 24 ± 2 29 ± 3 31 ± 3 
L-NAME 68 ± 7 58 ± 7 42 ± 7 55 ± 5 47 ± 5 48 ± 5 
Pre-L-NAME 
+ INDO 56 ± 4 36 ± 7
* 37 ± 6 36 ± 3 39 ± 5 38 ± 3 
L-NAME + 
INDO 71 ± 4
 63 ± 6 55 ± 5 61 ± 5 54 ± 5 49 ± 6 
 
* denotes significant difference from age-matched control, denotes significant 
difference in % tone after addition of blocker compared to pre-,  denotes 
significant difference in % tone between L-NAME alone and L-NAME and 
indomethacin,  p ≤ 0.05 
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3.4.1 Soleus Muscle Arteriolar Reactivity 
Cumulative addition of ACh produced a dose dependent vasodilation in all 
groups (Figure 3.2).  No differences were observed between the vasodilator 
responses from the prediabetic or acutely diabetic rats when compared to their age-
matched lean controls.  However, with chronic diabetes, the F20 group displayed a 
diminished maximal vasodilation to ACh compared to lean control rats (Figure 
3.2C).  No differences in sensitivity (IC50) to ACh were observed in any group.  
Incubation with L-NAME reduced the maximal vasodilation to ACh in both the 
fatty and lean rats during both pre- and acute diabetes.  The combined NOS and 
COX blockade produced no further decrement in vasodilation in either the fatty or 
lean rats at 7 and 13 weeks of age (Figure 3.2A&B).  During chronic diabetes, L-
NAME incubation reduced the vasodilation to ACh in the lean rats but had no 
effect in the arterioles from the fatty rats (Figure 3.2C).  The combined L-NAME 
and INDO blockade produced no further decrement in ACh-induced vasodilation in 
either the lean or fatty rats at 20 weeks of age (Figure 3.2C).   
Flow-induced vasodilation was diminished in the arterioles from the fatty 
rats during both overtly diabetic conditions (13 and 20 weeks of age) compared to 
lean age-matched controls (Figure 3.3B&C), but was similar between fatty and lean 
rats during prediabetes (Figure 3.3A).   
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Figure 3.2. Vasodilator Responses to ACh in the Presences of L-NAME and the Combination 
of L-NAME and INDO in Soleus Muscle Arterioles from Prediabetic (A), Acutely 
Diabetic (B) and Chronically Diabetic (C) Zucker Diabetic Fatty Rats and Age-
Matched Control Rats 
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Figure 3.3 Vasodilator Responses to Intraluminal Flow in Soleus Muscle Arterioles from 
Prediabetic (A), Acutely Diabetic (B) and Chronically Diabetic (C) Zucker 
Diabetic Fatty Rats and Age-Matched Control Rats
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 No differences in SNP-induced vasodilation were observed at any age 
between fatty and lean age-matched controls (Figure 3.4). 
 
3.4.2 Gastrocnemius Muscle Arteriolar Reactivity 
 The cumulative addition of ACh produced a dose dependent vasodilation in 
all arterioles studied (Figure 3.5).  No differences were observed between the 
vasodilator responses to ACh from the fatty groups and their age-matched lean 
controls at any point in the progression of type 2 diabetes (Figure 3.5).  No 
differences in sensitivity to ACh were observed between the fatty and lean rats at 
any timepoint.  Incubation with L-NAME reduced the maximal vasodilation to 
ACh in the lean rats at 7 and 13 weeks of age but not in the fatty rats at the same 
ages (Figure 3.5A&B).  The combination of L-NAME and INDO produced no 
further decrement in vasodilation to ACh in either lean control group at 7 and 13 
weeks of age (Figure 3.5A&B).  However, the combination of L-NAME and INDO 
diminished the vasodilation to ACh in the fatty rats during both pre-and acute 
diabetes (Figure 3.5A&B).  With chronic diabetes, L-NAME incubation did not 
reduce the vasodilation to ACh in the lean rats, however a reduction in vasodilation 
tended to be seen in the fatty rats during chronic diabetes (p = 0.065) (Figure 3.5C).  
However, INDO in combination with L-NAME produced a significant reduction in 
the dilation to ACh in both the fatty and lean rats during chronic diabetes (Figure 
3.5C).   
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Figure 3.4 Vasodilator Responses to SNP in Soleus Muscle Arterioles from Prediabetic (A),   
                             Acutely Diabetic (B) and Chronically Diabetic (C) Zucker Diabetic Fatty Rats and  
                             Age-Matched Control Rats 
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Figure 3.5 Vasodilator Responses to ACh in the Presences of L-NAME and the Combination 
of L-NAME and INDO in Gastrocnemius Muscle Arterioles from Prediabetic (A), 
Acutely Diabetic (B) and Chronically Diabetic (C) Zucker Diabetic Fatty Rats and 
Age-Matched Control Rats 
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 No differences occurred between fatty groups and their age-matched controls in 
flow-induced vasodilation (Figure 3.6).   
During prediabetes, vasodilation to SNP was increased in the fatty rats 
when compared to the lean controls of the same age (Figure 3.7A).  Vasodilation to 
SNP did not differ between the fatty and age-matched lean controls during either 
acute or chronic diabetes (Figure 3.7B&C).   
 
3.5 Discussion 
The purpose of the present study was 1) to determine if vasodilator 
dysfunction is present in prediabetes, 2) to examine the temporal relation of 
putative vasodilator dysfunction with the emergence of elevated arterial pressure 
and 3) to determine if arterioles from high-oxidative and low-oxidative glycolytic 
skeletal muscle are differentially affected by the progression of type 2 diabetes in 
the ZDF rat.  In the present study, the results demonstrate that endothelium-
dependent vasodilation is differentially affected by type 2 diabetes in muscles 
composed of different fiber types and having different oxidative capacities.  The 
maximal flow-induced and ACh-mediated vasodilator response of low-oxidative 
glycolytic skeletal muscle is preserved in prediabetes and acute diabetes, but the 
mechanisms by which ACh-induced vasodilation is achieved is modified in the 
prediabetic state.  Specifically, the NOS-dependent portion of ACh-stimulated 
vasodilation is absent in the gastrocnemius muscle arterioles of the prediabetic rats.  
In contrast, arterioles from the high-oxidative soleus muscle demonstrate 
endothelial dysfunction that becomes manifest after the development of type 2  
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Figure 3.6 Vasodilator Responses to Intraluminal Flow in Gastrocnemius Muscle Arterioles 
from Prediabetic (A), Acutely Diabetic (B) and Chronically Diabetic (C) Zucker 
Diabetic Fatty Rats and Age-Matched Control Rats 
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Figure 3.7 Vasodilator Responses to SNP in Gastrocnemius Muscle Arterioles from 
Prediabetic (A), Acutely Diabetic (B) and Chronically Diabetic (C) Zucker 
Diabetic Fatty Rats and Age-Matched Control Rats 
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diabetes.  Additionally, the results show that flow-induced vasodilation is 
diminished by type 2 diabetes earlier in the progression of the disease than is ACh-
mediated vasodilation.  This decrement in flow-induced vasodilation is coincident 
with the emergence of elevated arterial pressure in the ZDF rat.  The data also 
demonstrate that the decrement in ACh-stimulated vasodilator capacity with 
chronic diabetes is the consequence of a loss of the nitroxidergic signaling 
mechanism.   
Despite a preserved maximal vasodilator response in the gastrocnemius 
arterioles of the fatty rats, examination of the mechanisms of ACh-induced 
vasodilation reveals an alteration in endothelial function in both prediabetes and the 
diabetic conditions, resulting in a shift from predominately nitroxidergic to 
cyclooxygenase signaling mechanisms in the fatty rats.  In addition to its role in 
vasodilation, NO has a number of vasoprotective actions, such as the inhibition of 
vascular smooth muscle growth and migration, platelet aggregation and thrombosis, 
oxidation, monocyte adhesion, and inflammation (51).  Although the loss of NO 
production in these vessels does not adversely affect vasodilator function, it may 
however compromise these other vasoprotective effects, making the vessels 
susceptible to inflammatory damage, abnormal vascular remodeling or oxidative 
stress, and these in turn may influence the development of hypertension.  
Interestingly, a clear difference in the susceptibility to diabetes-associated 
endothelial dysfunction can be seen between high-oxidative and low-oxidative 
glycolytic muscles. 
  
51
Skeletal muscle blood flow at rest and during exercise throughout the 
progression of type 2 diabetes has not been examined, but the data of the present 
study suggest that impaired vasodilator function of the arterioles of high-oxidative 
muscle could have profound implications for blood flow regulation during 
locomotion in diabetic conditions since these muscles are the most highly recruited 
during activity (5, 63).  Moreover, the vasodilation in response to intraluminal flow 
is more sensitive to the diabetic condition than is ACh-mediated vasodilation, and 
is more likely to have an impact on exercise hyperemia. This speculation warrants 
further examination. 
Previous investigators have provided evidence for impaired vasodilator 
function of skeletal muscle arterioles in obese Zucker rats (OZR), but an evaluation 
of the development of this dysfunction has not previously been elucidated. These 
previous studies report a loss of endothelium-dependent vasodilation in the gracilis 
and cremaster muscles (33, 36, 37). Although these muscles are made up of 
predominately low-oxidative glycolytic muscle fibers the effects of diabetes on 
vasodilator function differ greatly from those of arterioles in the present study from 
muscle of a similar fiber type composition. The disparity in findings between these 
investigations and the present study may not be a function of the fiber type of the 
surrounding muscle per se but of the peculiarities in function of the cremaster and 
gracilis muscles themselves.  For example, the cremaster muscle, although a 
striated muscle, is not skeletal and not involved in gross skeletal movement.  
Unlike the cremaster muscle, the gracilis muscle is an adductor of the hindlimb 
made up of primarily fast-twitch muscle fibers (20% type I, 3% type IIA, 6% type 
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IIX, and 71 % type IIB) similar to the superficial gastrocnemius muscle (0% type I, 
0% type IIA, 8% type IIX, and 92% type IIB)(24).  However, although similarities 
in fiber populations between the gracilis and gastrocnemius muscle exist, 
differences in the blood flow response and consequently muscle recruitment during 
exercise are profound (5, 64) and may account for differences seen in the arteriolar 
function between investigations.   
The differences in findings between the present study and those of Frisbee 
et al. (33, 36, 37) may also be a function of the animal model examined.  The OZR 
rat is not necessarily an appropriate model of the prediabetic condition, as it may 
maintain subclinical hyperglycemia throughout its lifespan, and thus never progress 
to the overt diabetic condition.  For example, the progression of the OZR rat to 
overt diabetes has not been consistent in the literature, with some investigator 
reporting severe hyperglycemia ((33-37, 105), and others reporting little to no 
elevation in plasma glucose (14, 53, 75, 106), (128).  Moreover, even in cases 
where the plasma glucose is dramatically elevated, plasma insulin concentrations 
are often not reported (33-37, 105), making it difficult to determine whether the 
external environment of these vessels more closely resembles that of the 
prediabetic or overt diabetic condition. 
Using the of the ZDF model of type 2 diabetes, progressive changes in 
microvascular vasodilator capacity of the skeletal muscle vasculature during the 
development of type 2 diabetes were determined.  The data demonstrate that 1) 
although endothelium-dependent vasodilator responses are preserved in the low-
oxidative glycolytic gastrocnemius muscle arterioles, the loss of the endothelial 
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nitroxidergic signaling mechanism occurs concurrently with hyperglycemia and 
hyperinsulinemia in the prediabetic state, 2) an increase in smooth muscle cell 
sensitivity to exogenous NO occurs coincidently with the diminished endothelial 
NO signaling in the low-oxidative glycolytic gastrocnemius muscle arterioles, 3)  
there is a loss of endothelium-dependent, NO-mediated vasodilator response in 
arterioles from the high-oxidative soleus muscle, and 4) this dysfunction occurs 
coincidently with elevations in mean arterial pressure.  If applicable to the human 
condition, these data indicate that alterations in endothelial signaling and 
vasodilator capacity may contribute to the hypertension that occurs with type 2 
diabetes. 
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CHAPTER IV 
 
VASOCONSTRICTOR DYSFUNCTION AND STRUCTURAL 
ADAPTATIONS IN LOCOMOTOR SKELETAL MUSCLE ARTERIOLES 
FROM ZUCKER DIABETIC FATTY RATS IS DEPENDENT ON DISEASE 
PROGRESSION AND FIBER TYPE 
 
4.1 Overview 
 
 Altered vasoconstrictor reactivity or mechanical properties of skeletal 
muscle arterioles could impact both peripheral insulin resistance and hypertension 
observed in type 2 diabetes.  The purpose was to determine if increased 
vasoconstrictor reactivity and/or alterations in the structural properties of 1A 
arterioles isolated from both high-oxidative and low-oxidative glycolytic skeletal 
muscles is present during prediabetes as well as acute and chronic diabetes, and to 
determine if this putative dysfunction precedes the development of elevated arterial 
pressure in a rat model of type 2 diabetes.  Zucker Diabetic Fatty (ZDF) rats and 
lean age-matched controls were studied at 7 (prediabetes), 13 (acute diabetes) and 
20 (chronic diabetes) weeks of age.  Following measurement of arterial pressure, 
vasoconstrictor responsiveness to norepinephrine (NE), potassium chloride (KCl), 
and increasing intraluminal pressure (MYO) and passive mechanical properties 
were examined in isolated arterioles from the soleus and superficial gastrocnemius 
muscle.  Vasoconstriction to NE was enhanced in the gastrocnemius muscle 
arterioles during prediabetes and preceded the observed elevations in mean arterial 
pressure.  Vasoconstrictor responses to both NE and KCl were increased in the 
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soleus muscle arterioles during acute diabetes.  Vasoconstrictor responsiveness to 
both NE and MYO were increased in chronic diabetes, despite a diminished 
reactivity to KCl.  Alterations in the passive mechanical properties of arterioles 
from both muscles were observed throughout the progression of diabetes.  The data 
demonstrate that alterations in both the active and passive properties of low-
oxidative glycolytic skeletal muscle arterioles are present during prediabetes, and 
precede the development of type 2 diabetes. 
 
4.2 Introduction 
Type 2 diabetes affects approximately 15 million Americans, with an 
estimated 20 million more suffering from some degree of glucose intolerance (81).  
The presence of diabetes increases cardiovascular disease risk 2 to 6-fold over that 
in normal healthy adults (8, 10, 43, 54).  Hypertension, a common comorbidity of 
overt type 2 diabetes, often accompanies the diagnosis of type 2 diabetes with at 
least 40% of patients presenting with hypertension at the time of diabetes diagnosis 
(114).   
Overt type 2 diabetes is preceded by a prolonged period of impaired glucose 
regulation, termed prediabetes.  Prediabetes is characterized by peripheral insulin 
resistance, primarily in the skeletal muscle and adipose tissue, hyperinsulinemia, 
transient post-prandial and subclinical fasting hyperglycemia, hypertension, 
obesity, and dyslipidemia.  With chronic type II diabetes, abnormal microvascular 
function has been implicated in the development of a number of vascular 
complications, such as peripheral neuropathy, renal failure and blindness (17, 31, 
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91).  However, dysfunction of the skeletal muscle microvasculature may be 
manifest well before the onset of overt diabetes and contribute to both insulin 
resistance and hypertension seen during the prediabetic state.  Increases in 
vasoconstrictor responsiveness in the skeletal muscle could result in diminished 
insulin delivery, thus limiting plasma glucose disposal, and increase total peripheral 
resistance, contributing to hypertension.  Moreover, structural adaptations in the 
microvasculature related to hyperinsulinemia, hyperglycemia, or altered transmural 
pressure may result in vascular remodeling that could contribute to increases in 
peripheral vascular resistance as well as alter vasoreactivity.  However, neither the 
vasoconstrictor reactivity nor structural properties of arterioles have been 
adequately studied during the development of type 2 diabetes.    
The purpose of the present study was to examine alterations in the 
vasoconstrictor responsiveness and structural adaptations of skeletal muscle 
arterioles during the development of type 2 diabetes in a rat model.  The Zucker 
diabetic fatty (ZDF) rat was chosen because it has been shown to develop 
peripheral insulin resistance and subsequently, frank type 2 diabetes at predictable 
ages (27, 56).  Moreover, these rats develop many of the same conditions as 
prediabetes and type 2 diabetes in humans, such as obesity (11), hypertension (56, 
126), and abnormal blood lipid profiles (11, 27, 101, 102), making it a clinically 
relevant model.    
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4.3 Materials and Methods 
 Male ZDF rats were obtained from Charles Rivers Laboratories / Genetic 
Models Inc.  Diabetic (ZDF:fa/fa) and lean (ZDF: +/?) age-matched controls were 
studied at 7, 13, and 20 weeks of age to represent prediabetes, acute (1 week), and 
chronic (8 weeks) diabetes.  Animals were housed separately and allowed free 
access to Purina 5008 diet and water.  Animals were housed in a temperature 
controlled (23 ± 2 ºC) room with a 12:12 light-dark cycle.  All animal procedures 
were approved by the Texas A&M University Laboratory Animal Care Committee 
and complied by the guidelines of the National Research Council Guide for the 
Care and Use of Laboratory Animals (Washington DC: National Academy Press, 
Revised 1996).  
 
4.3.1 Animal Procedures  
Rats were anesthetized with sodium pentobarbital (65 mg/kg) via i.p. 
injection.  A polyurethane (Braintree Scientific, Micro-renathane; ID 0.36 mm, OD 
0.84 mm) catheter filled with heparinized saline was inserted into the caudal artery 
via a 1 cm incision in the ventral surface of the tail.  Electronically averaged mean 
arterial pressure was recorded while the rat was maintained under anesthesia.  
Following blood pressure measurement, blood was collected via cardiac puncture 
for assessment of plasma glucose and insulin content, and the heart removed.  
Whole heart and left and right ventricular masses were recorded.  The 
gastrocnemius-plantaris-soleus muscle complex was then carefully excised from 
each leg. 
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4.3.2 Microvessel Preparation  
Following excision, the gastrocnemius-plantaris-soleus muscle complex 
was placed in cold (4º C) physiological saline solution (PSS) that contained 145.0 
mM NaCl, 4.7 mM KCl, 2.0 mM CaCl2, 1.17 mMMgSO4, 1.2 mM NaH2PO4, 5.0 
mM glucose, 2.0 mM pyruvate, 0.02 mM EDTA, 3.0 mM MOPS buffer and 1 
g/100 ml BSA, pH 7.4.  Gastrocnemius and soleus muscle first-order (1A) 
arterioles were isolated with the aid of a dissecting microscope (Olympus SVH10) 
as previously described (71, 76).  In the soleus muscle, 1A arterioles were defined 
as the first arterial branch after the feed artery entered the muscle.  In the 
gastrocnemius muscle, 1A arterioles were defined as the first branch off the feed 
artery that runs over the superficial portion of the muscle.  The arterioles (length, 
0.5 - 1.0 mm; inner diameter, soleus muscle: 60-159 µm, gastrocnemius muscle: 
84-160 µm) were cleared of surrounding muscle fibers, removed from the muscle 
and placed in lucite chambers containing MOPS buffered PSS equilibrated to room 
air.  The arterioles were cannulated on both ends to micropipettes and secured with 
nylon suture.  After cannulation, the chambers were transferred to the stage of an 
inverted microscope (Olympus IX70) equipped with a video camera (Panasonic 
BP310), video caliper (Microcirculation Research Institute), and data acquisition 
system (MacLab) for recording of luminal diameter.  Arterioles were initially 
pressurized to 44 mmHg with two independent hydrostatic pressure reservoirs.  
Leaks were detected by pressurizing the vessel and then closing the reservoirs 
verifying that diameter remained constant.  Arterioles that exhibited leaks were 
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discarded.  Arterioles free of leaks were warmed to 37º C and allowed to develop 
initial spontaneous tone during a 30-60 min equilibration period.    
 
4.3.3 Experimental Design  
To determine whether vasoconstrictor function of the skeletal muscle 
arterioles is altered at different periods in the natural progression of type 2 diabetes, 
and if these alterations occur differentially in arterioles from predominately low-
oxidative glycolytic and high-oxidative skeletal muscles, constriction of 1A 
arterioles isolated from the superficial portion of the gastrocnemius and soleus 
muscle arterioles was measured in response to increasing intraluminal pressure 
(myogenic), norepinephrine (NE), and isotonic potassium chloride (KCl).  
Sensitivity of the arterioles to pharmacological agonists was assessed by 
calculating the EC50.   
 
4.3.4 Vasoconstriction to Intraluminal Pressure 
 After a steady-state spontaneous tone was achieved, arterioles were exposed 
to graded increases in intraluminal pressure.  This was accomplished by altering the 
height of the independent fluid reservoirs.  Diameter measurements were made in 
response to incremental increases and decreases in pressure from 0-99 in 11 mmHg 
increments.   
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4.3.5 Vasoconstriction to Pharmacological Agonists 
 Concentration-response relations to the cumulative addition of NE (10-9 to 
10-4) and KCl (10-100 mM) were determined.  These vasoconstrictors were chosen 
because they mediate constriction through receptor dependent (NE) and 
independent (KCl) mechanisms.  The vessels were allowed to equilibrate between 
successive dose responses and were discarded unless at least 20% baseline tone 
was achieved prior to addition of vasoconstrictor agents. 
 
4.3.6 Passive Mechanical Properties 
 To determine whether alterations in the mechanical or structural properties 
of arteries occurs with the development of type 2 diabetes, a second set of arterioles 
was used to measure passive pressure-diameter relations, circumferential stress and 
strain and incremental stiffness.  Previous investigations of arteries from normal 
and hypertensive rats indicate that the structural behavior of a vessel segment may 
remain unchanged despite an alteration in the material properties of the vascular 
wall (89).  Therefore, the passive pressure-diameter relation and measures of 
stiffness were used to assess the structural behavior and material properties of the 
arterial wall, respectively. These vessels were dissected and cannulated as 
described above, but placed in calcium-free PSS.  Arterioles were allowed to 
equilibrate at 37ºC while pressurized at 44 mmHg  to induce complete 
vasorelaxation.  The vessels were then exposed to incremental increases in 
intraluminal pressure from 0-99 mmHg in 11 mmHg increments.  Maximal 
diameter at each pressure step was recorded.  Following the passive pressure-
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diameter assessment, vessels were allowed to equilibrate at 44 mmHg for 5 minutes 
then fixed in 20% Bouins fixative for 10 min.  Following fixation, vessels were 
removed from the cannulae and frozen in OCT for histological analysis.  Frozen 
samples were sectioned in a cryostat at 7 µm, and stained with Weigarts 
hematoxylin (Sigma #HT1079) and Maissons trichrome stain (Sigma #HT15), 
which stains the smooth muscle red and connective tissue blue.  Medial wall cross-
sectional area was measured from the stained sections.  Medial wall thickness at 
each pressure step was then calculated according to the following equation 
V = π [(ID + 2WT)2  ID2]L = π[(IDo + 2WTo)2  (IDo)2]L 
where V is wall volume (a constant), ID is inner diameter at any given pressure 
other than zero, WT is wall thickness, L is vessel segment length, IDo is original 
diameter measured at 0 cmH2O, and WTo is wall thicknessmeasured at 0 cmH2O.  
The vadidity of estimating WT at intraluminal pressures other than 60 cmH2O is 
based on the assumption that wall volume remains constant with changes in 
diameter.  Both circumferential Cauchy (σ) and circumferential second Piola-
Kirchoff stresses (S) were calculated from intraluminal pressure (IP), inner 
diameter, and wall thickness in the following manner 
σθ = (IP X ID)/(2WT) 
and 
Sθ = σθ X [1/(λθ)2] 
where λθ is the principal stretch (extension) ratio in the circumferential direction, 
which equals current inner radius(r) divided by initial inner radius (R).  In these 
arterioles, λθ can be accurately represented by measurements of the inner radius 
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because the wall thickness is minimal, i.e., on average, wall thickness is 
approximately 4% of outer diameter.  Because the deformations of the arterioles are 
large, principal stretch ratios were appropriate measures.  The Cauchy stress, or 
true stress, is defined as the actual force acting on an oriented differential area in 
the current (deformed) configuration and is related to the principal stretch ratio (λ).  
The second Piola-Kirchoff stress, on the other hand, is defined as the theoretical 
force acting on an oriented differential area in the reference (undeformed) 
configuration, and is conjugate to the Greens strain (E), where conjugate indicates 
that the stress can be determined directly from an energy function by differentiating 
with respect to the conjugate measure of deformation.  The circumferential 
Greesns strain is calculated in the following manner 
Eθ = ½ [(λθ)2 -1] 
Stiffness can be determined from either the stress/strain or stress/stretch relations.  
In the present study, incremental stiffness was calculated as change in stress/ 
change in strain for each datum point.  Incremental stiffness points were plotted as 
a function of their corresponding stress points, and linear regression analysis was 
used to calculate the slope of that relation (76).   
 
4.3.7 Solutions and Stocks 
 Stock solutions of drugs were prepared in distilled water and frozen.  Fresh 
dilutions of these stocks were prepared daily.  All drugs were purchased from 
Sigma Chemical (St. Louis, MO). 
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4.3.8 Data Presentation and Statistical Analysis 
 Vasoconstrictor responses to NE and KCl were recorded as actual diameters 
and expressed as a percentage of possible constriction according to the following 
formula for analysis: 
Diameter (% tone) = 100-[(Ds  Db)/(Db) *100]  
Where Ds is the steady-state inner diameter recorded after each dose or change in 
intraluminal pressure, and Db is the initial baseline inner diameter before the first 
addition of drug or change in intraluminal pressure.  Myogenic vasoconstriction 
and passive pressure-diameter relations are presented as a percentage of the 
maximum diameter obtained at 44 mmHg.  Spontaneous tone is presented at a 
percentage of maximal intraluminal diameter.  Repeated measures analysis of 
variance (ANOVA) was used to determine differences between age-matched 
diabetic and control groups for all dose responses.  Fisher protected least significant 
difference post hoc was used where appropriate.  For animal characteristics data, a 
one-way ANOVA was used to determine significant differences between diabetic 
and age-matched controls.  All data are presented as mean ± SEM.  Significance 
was set at P ≤ 0.05.  
 
4.4 Results 
 Body mass was 27% greater in the 7 week old prediabetic fatty rats (F7) 
than the age-matched lean (L7) rats.  There were no differences in body mass 
between the diabetic or lean groups at either 13 or 20 weeks of age (Table 4.1).   
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Table 4.1. Characteristics of Prediabetic (7), Acute (13) and Chronically (20) 
Diabetic Fatty (F) and Lean (L) Age-Matched Control Zucker Diabetic Fatty 
Rats 
 
Weeks of Age 7 13 20 
Group 
(n) 
L 
(15) 
F 
(15) 
L 
(13) 
F 
(14) 
L 
(13) 
F 
(11) 
Body mass (g) 201 ± 4 256 ± 5* 358 ± 4 377 ± 14 435 ± 5 410 ± 14 
Soleus muscle 
mass (mg) 109 ± 6 121 ± 6 194 ± 6 175 ± 7 227 ± 5 165 ± 9
* 
Soleus-to-body 
mass ratio (%) 
0.05 ± 
0.01 
0.05 ± 
0.01 
0.05 ± 
0.01 
0.04 ± 
0.01* 
0.05 ± 
0.01 
0.04 ± 
0.01* 
Gastrocnemius 
muscle  
mass (g) 
0.99 ± 
0.07 
1.03 ± 
0.03 
1.88 ± 
0.02 
1.45 ± 
0.05* 
2.07 ± 
0.16 
1.35 ± 
0.10* 
Gastrocnemius-
to-body mass 
ratio (%) 
0.49 ± 
0.13 
0.40 ± 
0.04* 
0.53 ± 
0.03 
0.39 ± 
0.02* 
0.47 ± 
0.13 
0.33 ± 
0.08* 
Whole heart 
mass (g) 
0.70 ± 
0.01 
0.77 ± 
0.02* 
1.07 ± 
0.02 
1.00 ± 
0.03* 
1.29 ± 
0.03 
1.07 ± 
0.02* 
Heart-to-body 
mass ratio (%) 
0.35 ± 
0.01 
0.30 ± 
0.01* 
0.30 ± 
0.01 
0.27 ± 
0.01* 
0.30 ± 
0.01 
0.26 ± 
0.01* 
Left ventricle 
mass (mg) 540 ± 13 693 ± 15
* 810 ± 12 761 ± 22 993 ± 24 835 ± 17*
Right ventricle 
mass (mg) 129 ± 10 148 ± 7 218 ± 12 197 ± 12 231 ± 7 196 ± 7
* 
 
* Denotes significant difference from age-matched control, P ≤ 0.05, (n) is the 
number of animals 
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Although the absolute mass of the gastrocnemius muscle did not differ between the 
fatty and lean rats during prediabetes, the gastrocnemius muscle-to-body mass ratio 
was lower in the fatty rats.  With acute diabetes, gastrocnemius muscle mass was 
reduced in the fatty (F13) rats when compared to the lean controls (L13), and these 
differences persisted when expressed relative to body mass.  Although no 
differences were found in the absolute mass of the soleus muscle in acute diabetes, 
the muscle-to-body mass ratio was lower in the fatty rats (Table 4.1).  Similar 
differences were seen in chronic diabetes with soleus and gastrocnemius muscle 
masses being lower in the fatty (F20) rats compared to age-matched lean (L20) rats, 
and these differences persisted when expressed relative to body mass (Table 4.1). 
Heart mass was higher (10.4%) in the prediabetic rats, however the heart-to-body 
mass ratio was lower in the F7 rats compared to age-matched controls (Table 4.1).  
Acute and chronic diabetes resulted in decreased heart mass (6.5% and 17%, 
respectively) and this difference persisted when expressed relative to body mass 
(Table 4.1).   
Soleus and gastrocnemius muscle arteriolar maximal diameters did not 
differ between groups at any stage in the progression of type 2 diabetes (Table 4.2).  
Spontaneous tone in the soleus muscle arterioles did not differ between groups 
during any stage in the progression of type 2 diabetes (Table 4.2).  Spontaneous 
tone in gastrocnemius muscle arterioles was larger in the fatty rats during chronic 
diabetes compared to age-matched controls prior to the KCl dose relation, but at no 
other point in the progression of the disease, and at no time point prior to the NE 
dose relation (Table 4.2). 
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Table 4.2. Soleus and Gastrocnemius Muscle Maximal Diameters and 
Spontaneous Tone of 1A Arterioles from Prediabetic (7), Acute (13) and 
Chronically (20) Diabetic Fatty (F) and Lean (L) Age-Matched Control 
Zucker Diabetic Fatty Rats Prior to Active Responses 
 
 
 Muscle 
Soleus Gastrocnemius 
Age 
(wks) Grp 
Max 
Diam 
(µm) 
Pre-KCl 
Tone (%) 
Pre-NE 
Tone (%) 
Max 
Diam 
(µm) 
Pre-KCl 
Tone (%) 
Pre-NE 
Tone (%) 
L 97 ± 4 36.4 ± 4.8 33.5 ± 4.2 101 ± 5 
 
30.5 ± 3.8 32.4 ± 5.2
7 F 93 ± 4 
 
37.9 ± 5.7 33.7 ± 5.5 99 ± 3 28.7 ± 6.0 22.6 ± 3.6
L 117 ± 5 37.9 ± 4.1 47.6 ± 4.5 126 ± 5 
 
26.5 ± 4.0 33.6 ± 4.1
13 F 115 ± 7 
 
37.3 ± 4.4 55.1 ± 6.3 124 ± 4 24.7 ± 4.0 30.7 ± 3.2
L 128 ± 4 43.5 ± 7.2 40.8 ± 5.2 124 ± 4 
 
22.9 ± 2.3 32.5 ± 5.7
20 F 122 ± 5 32.6 ± 5.8 42.2 ± 5.5 119 ± 6 31.6 ± 3.7* 36.1 ± 5.3
  
* Denotes significant difference from age-matched control, P ≤ 0.05 
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Mean arterial pressure (MAP) did not differ between fatty and lean rats 
during prediabetes, but was significantly elevated after the onset of overt diabetes 
(Figure 4.1).  Plasma glucose was elevated in all fatty groups compared to age-
matched controls (Figure 4.1).  Plasma insulin was elevated in the prediabetic rats 
relative to age-matched controls, but below control values in both the acute and 
chronic diabetic conditions (Figure 4.1).  
 
4.4.1 Reactivity to Norepinephrine 
 Vasoreactivity to NE was greater in the soleus muscle arterioles from 
acutely diabetic rats compared to lean age-matched controls, but not at any other 
stage in the progression of type 2 diabetes (Figure 4.2).  Conversely, vasoreactivity 
to NE was greater during both pre- and chronic diabetes in gastrocnemius muscle 
arterioles of the fatty rats compared to lean age-matched controls, but not during 
acute diabetes (Figure 4.3).   
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 Figure 4.1. Values of Plasma Glucose Displayed as Difference from Control (A), Plasma 
Insulin (B) and Mean Arterial Pressure (C) of Prediabetic (7), Acutely (13) and 
Chronically (20) Diabetic Fatty (F) and Lean (L) Age-Matched Control Zucker 
Diabetic Fatty Rats 
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Figure 4.2. Vasoconstrictor Responses to Norepinephrine in Soleus Muscle Arterioles from 
Prediabetic (A), Acutely Diabetic (B) and Chronically Diabetic (C) Zucker 
Diabetic Fatty Rats and Age-Matched Control Rats 
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Figure 4.3. Vasoconstrictor Responses to Norepinephrine in Gastrocnemius Muscle Arterioles 
from Prediabetic (A), Acutely Diabetic (B) and Chronically Diabetic (C) Zucker 
Diabetic Fatty Rats and Age-Matched Control Rats 
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4.4.2 Myogenic Response 
 No differences were found in the myogenic response at any stage in the 
progression of type 2 diabetes in arterioles from the soleus muscle (Figure 4.4).  
Myogenic reactivity was greater in gastrocnemius muscle arterioles of the 
chronically diabetic rats versus age-matched controls (Figure 4.5).  No other 
differences were found.   
 
4.4.3 Reactivity to Isotonic Potassium Chloride 
 Vasoreactivity to isotonic KCl was greater in acutely diabetic soleus muscle 
arterioles relative to age-matched controls (Fig 4.6).  No other differences were 
found in reactivity to KCl in the soleus muscle arterioles.  A reduced reactivity to 
KCl was found in gastrocnemius muscle arterioles from the acutely and chronically 
diabetic rats, whereas no differences occurred during prediabetes (Figure 4.7). 
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Figure 4.4. Vasoconstrictor Responses to Myogenic Stimuli in Soleus Muscle Arterioles from 
Prediabetic (A), Acutely Diabetic (B) and Chronically Diabetic (C) Zucker 
Diabetic Fatty Rats and Age-Matched Control Rats  
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Figure 4.5. Vasoconstrictor Responses to Myogenic Stimuli in Gastrocnemius Muscle 
Arterioles from Prediabetic (A), Acutely Diabetic (B) and Chronically Diabetic 
(C) Zucker Diabetic Fatty Rats and Age-Matched Control Rats  
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Figure 4.6. Vasoconstrictor Responses to Isotonic Potassium Chloride in Soleus Muscle 
Arterioles from Prediabetic (A), Acutely Diabetic (B) and Chronically Diabetic 
(C) Zucker Diabetic Fatty Rats and Age-Matched Control Rats 
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Figure 4.7. Vasoconstrictor Responses to Isotonic Potassium Chloride in Gastrocnemius 
Muscle Arterioles from Prediabetic (A), Acutely Diabetic (B) and Chronically 
Diabetic (C) Zucker Diabetic Fatty Rats and Age-Matched Control Rats  
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4.4.4 Vessel Morphology 
No differences in maximal diameter were found in either the soleus or 
gastrocnemius muscle arterioles at any stage of diabetes (Table 4.3).  Medial wall 
cross-sectional area and wall-to-lumen ratio were larger in the prediabetic 
gastrocnemius muscle arterioles compared to lean controls.  No other differences in 
wall thickness or wall-to-lumen ratio were observed in arterioles from either 
muscle at any stage of diabetes.  
4.4.5 Passive Pressure-Diameter, Stress/Strain and Arteriolar Stiffness 
During prediabetes, the passive pressure-diameter relation did not differ 
between the soleus muscle arterioles from the fatty or lean age-matched control rats 
(Figure 4.8A).  However, stress/strain analysis revealed greater circumferential 
stress in the soleus muscle arterioles from the prediabetic rats (Figure 4.8B). 
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Table 4.3. Morphological Characteristics of 1A Arterioles from the Soleus and 
Gastrocnemius Muscles of Prediabetic (7), Acute (13) and Chronically (20) 
Diabetic Fatty (F) and Lean (L) Age-Matched Control Zucker Diabetic Fatty 
Rats 
 
 
Soleus 
Weeks 
of Age 
Group 
(n/n) 
Maximal 
Diameter 
(µm) 
Wall 
Thickness 
(µm) 
Wall Cross 
Sectional 
Area (µm2) 
Wall to 
Lumen 
Ratio (%) 
Stiffness 
Parameter
L 
(15/9) 94 ± 6 7.9 ±0.9 1218 ± 193 9.6 ± 1.1 5.8 ± 0.8 7 F 
(16/11) 108 ± 4 7.5 ± 1.0 1615 ± 110 9.0 ± 1.9 5.5 ± 0.7 
L 
(11/9) 117 ± 10 9.2 ± 1.4 2115 ± 390 7.8 ± 0.5 3.4 ± 0.8 13 F 
(12/8) 117 ± 7 8.2 ± 1.0 2275 ± 621 7.0 ± 0.4 3.7 ± 0.5 
L 
(12/11) 126 ± 8 7.7 ± 1.0 1863 ± 214 6.0 ± 0.8 5.9 ± 1.0 20 F 
(11/9) 128 ± 7 7.0 ± 0.5 1807 ± 301 5.6 ± 0.3 3.3 ± 0.5
* 
Gastrocnemius 
Weeks 
of Age 
Group 
(n/n) 
Maximal 
Diameter 
(µm) 
Wall 
Thickness 
(µm) 
Wall Cross 
Sectional 
Area (µm2) 
Wall to 
Lumen 
Ratio (%) 
Stiffness 
Parameter
L 
(14/9) 105 ± 6 10.0 ± 0.9 2142 ± 358 8.8 ± 0.8 7.4 ± 1.3 7 F 
(14/8) 112 ± 7 12.2 ± 0.4 3780 ± 749
* 11.8 ± 0.8* 6.1 ± 1.1 
L 
(12/8) 126 ± 7 13.0 ± 1.8 3772 ±848 10.4 ± 1.2 4.8 ± 0.7 13 F 
(11/8) 131 ± 11 11.4 ± 1.1 3013 ± 453 9.6 ± 1.2 4.7 ± 0.8 
L 
(12/9) 138 ± 9 10.6 ± 0.9 2528 ± 313 8.1 ± 0.8 6.8 ± 1.6 20 F 
(11/9) 127 ± 11 10.7 ± 1.1 2651 ± 410 10.3 ± 1.1 5.5 ± 1.0 
 
* Denotes significant difference from age-matched control, P ≤ 0.05, (n/n) number 
of vessels measured for diameter / number of vessels measured with histology 
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 Figure 4.8. Passive Pressure-Diameter Relationships (A,C,E) and Circumferential Stress and 
Strain Relationships (B,D,F) of Soleus Muscle Arterioles from Prediabetic, 
Acutely and Chronically Diabetic and Lean Age-Matched Control Zucker 
Diabetic Fatty Rats 
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Arterioles from the gastrocnemius muscle of prediabetic rats displayed larger 
relative diameters at low intraluminal pressures when compared to age matched 
control vessels (Figure 4.9A), and this was reflected in a lower circumferential 
strain in these vessels (Figure 4.9B).  No differences in the incremental stiffness 
were observed during prediabetes in arterioles from either the soleus or 
gastrocnemius muscle (Table 4.3). 
 Larger relative diameters were observed in soleus muscle arterioles from the 
acutely diabetic rats compared to age-matched controls during assessment of the 
passive pressure-diameter relation (Figure 4.8C).  However, no differences in the 
circumferential stress or strain were observed (Figure 4.8D).  The passive-pressure 
diameter relation of gastrocnemius muscle arterioles from acutely diabetic rats was 
unaltered (Figure 4.9C).  However, circumferential stress was greater in these 
arterioles (Figure 4.9D).  No differences in incremental stiffness were observed 
during acute diabetes in arterioles from either muscle examined (Table 4.3). 
 Larger relative diameters were observed in response to high intraluminal 
pressure in soleus muscle arterioles from chronically diabetic rats (Figure 4.8E).  
Concurrently, circumferential strains were greater (Figure 4.8F).  In addition, 
circumferential stress was also higher in the soleus muscle arterioles of the 
chronically diabetic rats (Figure 4.8F), resulting in a lower incremental stiffness in 
these arterioles (Table 4.3).  Larger relative diameters were also observed in the 
gastrocnemius muscle arterioles of the chronically diabetic rats pressures (Figure 
4.9E), and despite a normalization in circumferential stress in these arterioles,  
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Figure 4.9. Passive Pressure-Diameter Relationships (A,C,E) and Circumferential Stress and 
Strain Relationships (B,D,F) of Gastrocnemius Muscle Arterioles from 
Prediabetic, Acutely and Chronically Diabetic and Lean Age-Matched Control 
Zucker Diabetic Fatty Rats 
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circumferential strain was higher (Figure 4.9F).  No differences in incremental 
stiffness were observed in the chronically diabetic gastrocnemius muscle arterioles 
(Table 4.3).  
4.5 Discussion 
The purpose of the present study was to determine 1) whether type 2 
diabetes alters vasoconstrictor reactivity of skeletal muscle arterioles, 2) whether 
these putative changes precede the development of elevated arterial pressure, 3) 
whether structural vascular remodeling and alterations in the passive mechanical 
properties of skeletal muscle arterioles occur during the progression of type 2 
diabetes, and 4) whether  vasoconstrictor reactivity and passive mechanical 
properties from arterioles of high-oxidative and low-oxidative glycolytic skeletal 
muscles are differentially affected by the progression of type 2 diabetes.  The data 
demonstrates that increases in vasoconstrictor reactivity in the low-oxidative 
glycolytic gastrocnemius muscle arterioles occurs during prediabetes, and 
therefore, precedes both the development of overt diabetes and elevated arterial 
pressures in the ZDF rat.  The results also indicate that this prediabetic increase in 
vascoconstrictor reactivity to NE and KCl is unique to the low-oxidative glycolytic 
skeletal muscle arterioles, and that these enhanced responses are variable 
throughout the progression of the disease.  In contrast, arterioles from the high-
oxidative soleus muscle only have higher vascoconstrictor reactivity during the 
acute diabetic condition, and this increase in vasoconstrictor responsiveness 
coincides with the emergence of elevated arterial pressure.  Finally, the data 
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demonstrates that arteriolar morphological and mechanical properties are altered 
during the prediabetic condition. 
Chronic type 2 diabetes is often accompanied by hypertension.  In fact, 
hypertension is frequently present at the time of diabetes diagnosis, and may be the 
result of enhanced arteriolar vasoconstrictor responsiveness present during the 
prediabetic state.  During the progression of type 2 diabetes the external 
environment of the arterioles is in flux as a result of the patients changing 
metabolic status, resulting in disparate stimuli for alterations in vascular structure 
and vasoreactivity throughout the progression of the disease.  During prediabetes, 
when hyperinsulinemia and insulin resistance are coexistant, it is unknown whether 
increased vascular resistance will result from an insulin resistance-mediated 
diminution of insulin as a vasodilator (50) or if hyperinsulinemia leads to an 
increase in vasoconstriction via activation of the sympathetic nervous system (18, 
73, 82, 104).  Despite an established relation between insulin resistance and 
hypertension (29, 94), the role of altered vasoreactivity in the development of 
insulin resistance-related hypertension has not been established.  
Enhanced vasoconstrictor responsiveness in the prediabetic state could 
contribute to the development of hypertension prior to overt diabetes.  Result from 
the present study demonstrate elevated vasoconstrictor reactivity in low-oxidative 
glycolytic skeletal muscle in prediabetic ZDF rats. Previous examinations of the 
vasoconstrictor responsiveness of arterioles from insulin resistant humans and 
animals have produced inconsistent results.  For example, vasoconstriction to 
norepinephrine (NE) has been shown to be either unchanged in insulin resistant 
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human subcutaneous fat arterioles (97) or increased in gracilis muscle arterioles 
from obese Zucker rats (OZR) (105), a low-oxidative glycolytic skeletal muscle.  
Neither the OZR rat nor insulin resistant humans are necessarily appropriate 
models of the prediabetic condition, since both may maintain subclinical 
hyperglycemia throughout their lifespan.  For example, the progression of the OZR 
rat to overt diabetes has not been consistent in the literature, with some investigator 
reporting severe hyperglycemia  (33-37, 105) while others report little to no 
elevation in plasma glucose (14, 53, 75, 106, 128).  Moreover, even in cases where 
the plasma glucose is elevated, plasma insulin concentrations are often unknown 
(33-37, 105), making it difficult to assess whether the external environment of 
these vessels more closely resembles that of the prediabetic or overt diabetic 
condition.     
Data in the present study are similar to those of previous investigators (105) 
in that vasoconstrictor responses to NE were enhanced in the low-oxidative 
glycolytic skeletal muscle during both pre- and chronic diabetes. This enhanced 
adrenergic vasoreactivity in the prediabetic state may indeed contribute to the 
hypertension which occurs with overt diabetes.  Interestingly, the adrenergic 
vasoreactivity of the high-oxidative soleus muscle arterioles is unaffected during 
prediabetes, but is elevated during the acutely diabetic condition, which coincides 
with a large reduction in plasma insulin, increase in the level of hyperglycemia, and 
the development of elevated mean arterial pressure.  Thus it appears that arterioles 
from high-oxidative and low-oxidative glycolytic skeletal muscles respond 
differently to these changing conditions. 
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Increases in adrenergic vasoconstrictor responsiveness in the low-oxidative 
glycolytic muscle arterioles precede and may be causally related to the 
development of elevations in arterial pressure, as this skeletal muscle is the 
predominant type in muscles, making up approximately 70% of the total skeletal 
muscle mass in rats (24).  Increase s in adrenergic reactivity in the high-oxidative 
soleus muscle arterioles may be the consequence of either this elevated arterial 
pressure, the reduction in plasma insulin, or the pronounced elevation in plasma 
glucose.    
  Despite either unchanged or elevated adrenergic and myogenic 
vasoreactivity, KCl-induced vasoconstriction was found to be both increased and 
decreased at different time points during the progression of type 2 diabetes, even 
within the same muscle.  The decreases in KCl-induced vasoconstriction present in 
the low-oxidative glycolytic gastrocnemius muscle occurred concurrently with the 
increases in both the adrenergic vasoreactivity and myogenic responsiveness, 
indicating that a generalized loss in smooth muscle contractility does not occur, but 
rather specific signaling mechanisms are adversely altered during acute and chronic 
diabetes.  Similar variability in vasoconstrictor responses have been reported in the 
literature, for example, vasoconstriction to angiotensin II and endothelin-1 have 
been shown to be either increased (70), unchanged (105) or decreased (122) with 
overt disease.  Moreover, myogenic constriction has been shown to be both 
increased in gracilis muscle arterioles from OZR rats (35) and decreased in 
subcutaneous adipose tissue arterioles from type 2 diabetic patients (97).  
Nonetheless, the present study demonstrates that an increase in the vasoconstrictor 
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reactivity of low-oxidative glycolytic skeletal muscles exists during the prediabetic 
state and may contribute to the later development of elevated mean arterial 
pressure.     
 In addition to changes in the vasoreactivity of the skeletal muscle 
arterioles, alterations in the vascular structure and mechanical properties may also 
contribute to the development of hypertension in type 2 diabetes.  Stiffer arteries 
independent of increases in wall thickness have been reported in patients with 
impaired fasting glucose (95).  Moreover, changes in vessel wall structural 
characteristics have been observed in type 2 diabetic human adipose arterioles (87, 
97) and type 2 diabetic coronary arterioles (125) and have been proposed to 
contribute to peripheral insulin resistance and hypertension seen with type 2 
diabetes.  In these studies, increases in medial wall thickness, medial cross-
sectional area, and wall-to-lumen ratio have been reported.  However, these 
structural adaptations have not been consistently observed, as others have reported 
decreases in medial wall thickness, wall-to-lumen ratio, and decreased distensibility 
in gracilis muscle arterioles from OZR rats (34).  Unlike the previous study (34), 
medial wall cross-sectional area and wall-to-lumen ratio were increased in the low-
oxidative glycolytic gastrocnemius muscle arterioles during prediabetes in the 
present study.  Moreover, an increase in the distensibility of these arterioles to low 
intraluminal pressures was observed.  In contrast, no changes in vessel wall 
morphology were observed in the soleus muscle arterioles at any timepoint or in the 
gastrocnemius muscle arterioles at any other stage in the progression of type 2 
diabetes, which is suggestive of a specific sensitivity of the gastrocnemius 
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arterioles to systemic hyperinsulinemia that was not present in the high-oxidative 
soleus muscle arterioles. This increase in medial wall cross-sectional area may have 
placed a physical limitation on changes in arteriolar diameter and resulted in the 
diminished circumferential strains observed in these vessels.   
Examination of the circumferential stresses and strains of the gastrocnemius 
muscle arterioles throughout the progression type 2 diabetes indicate that the 
mechanical properties of the vessel are differentially altered by their changing 
external environment.  Although smooth muscle hypertrophy is a consequence of 
only the prediabetic state, the circumferential strain in the gastrocnemius arterioles 
is progressively increasing relative to the age-matched controls as overt diabetes 
develops and is maintained.  Moreover, the increased wall stress experienced 
during acute diabetes in these arterioles may be contributing to a rearrangement of 
vascular components (52) and, subsequently the large increase in distensibility and 
circumferential strain observed in the chronic diabetic state. 
The soleus muscle arteriolar mechanical properties appear to be most 
effected by chronic diabetes in that the most dramatic alteration in vessel wall 
mechanics was observed in the chronically diabetic soleus muscle arterioles.  The 
data demonstrate increases in both circumferential stress and strain that result in a 
decreased arteriolar stiffness.  This is consistent with vascular changes observed in 
other hypertensive rat models, for example, an early decrease in stiffness of 
mesenteric small arteries has been reported from spontaneously hypertensive rats 
(SHR) (65).  Moreover, the stiffness characteristics of mesenteric arterioles differ 
as a result of branch order in the SHR rat, such that in stroke prone SHR rats 
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second-order mesenteric arterioles exhibit increased stiffness while third-order 
arterioles of the same vascular bed display decreased stiffness (46).  Thus, although 
the gastrocnemius muscle arteriolar morphology appears to be sensitive to the 
prediabetic state, the passive mechanical properties of the arterioles of the soleus 
muscle are most affected by chronic diabetes at which time elevations in mean 
arterial pressure may also be contributing to altered vessel wall mechanics. 
In summary, increased adrenergic vasoreactivity is present in arterioles 
from both high-oxidative and low-oxidative glycolytic skeletal muscles, and this 
enhanced adrenergic reactivity in low-oxidative glycolytic muscle arterioles 
precedes the development of elevated arterial pressure.  Enhanced vasoconstrictor 
responsiveness is not a generalized phenomenon, since increases in myogenic 
responsiveness are not present until chronic diabetes and then only in the 
gastrocnemius muscle arterioles, and KCl-induced vasoconstriction is both 
enhanced and diminished depending on the stage in the progression of diabetes and 
skeletal muscle being examined.  Moreover, prediabetes results in a hypertrophic 
response in arterioles of the low-oxidative glycolytic gastrocnemius muscle 
arterioles that is not present following the development of overt diabetes. Lastly, 
although no changes in vessel morphology were observed with overt diabetes, the 
chronic diabetic condition led to increased distensibility in arterioles from both 
high-oxidative and low-oxidative glycolytic skeletal muscles, and a decreased 
stiffness in the high-oxidative muscle arterioles.  If these findings are relevant to 
the development of type 2 diabetes in humans, they indicate that enhanced 
adrenergic vasoconstrictor reactivity in the prediabetic state concurrent with altered 
  
88
vascular mechanical properties may be contributing to the development of both 
overt type 2 diabetes and hypertension.  
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CHAPTER V 
 
SUMMARY AND CONCLUSIONS 
5.1 Overview 
Using the ZDF model, we were able to examine differences in the 
vascoconstrictor and vasodilator responsiveness, as well as passive mechanical 
properties of resistance arterioles from high-oxidative and low-oxidative glycolytic 
skeletal muscles throughout the development of type 2 diabetes.  Ultimately, it is 
not an alteration to any specific agonist of vasoconstriction or vasodilation that 
appears important singly, but rather how these influences along with structural 
adaptations might interact to influence total peripheral resistance and glucose 
uptake.   
To that end, comparisons were made between the fatty genotype of the ZDF 
rat and its lean age-matched control in order to account for changes in vessel 
function that may be occurring as a result of maturation independent of the 
development of type 2 diabetes.  Differences in vasomotor responses over time 
were selected to represent three distinct conditions in the progression to overt type 
2 diabetes. The 7 week old ZDF animals represent the prediabetic condition, as 
both plasma insulin and glucose are significantly elevated.  By 13 weeks of age, the 
fatty rats experience a significant loss of pancreatic function resulting in profound 
hyperglycemia with normal to below normal plasma insulin concentrations.  The 
loss of pancreatic function is reported to occur at approximately 12 weeks in this 
animal, making this time point representative of an acutely diabetic condition.  
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Lastly, the 20 week old fatty rats remain hyperglycemic and hypoinsulinemic and 
are representative of uncontrolled chronic diabetes. 
 
5.2 Prediabetes 
Maximal vasodilator responsiveness to ACh and intraluminal flow was 
unaltered in prediabetes in both the soleus and gastrocnemius muscle 1A arterioles.  
However, the mechanisms by which the gastrocnemius muscle arterioles achieve 
ACh-induced vasodilation were altered in the fatty rats.  Blockade of NOS by L-
NAME failed to reduce the vasodilator response in the gastrocnemius muscle 
arterioles from the prediabetic and acute diabetic fatty rats, in contrast to the 
approximately 50% reduction in ACh-induced vasodilation in the control arterioles.  
In addition, blockade of both NOS and cyclooxygenase failed to further reduce the 
vasodilation to ACh in the control rats, but produced a reduction in vasodilation in 
the fatty rats similar to that seen in the controls with L-NAME alone.  Thus, there 
was a shift in the endothelium signaling mechanisms in the prediabetic fatty rats 
from a primarily NO-mediated vasodilation to a prostaglandin-mediated 
vasodilation.  Accompanying this decrease in the endothelial nitroxidergeric 
signaling was an increased responsiveness to SNP-induced vasodilation, indicating 
that smooth muscle reactivity to NO is enhanced in these arterioles.  This enhanced 
sensitivity to NO may be the result of a diminished stimulated, but not basal 
bioavailability of NO in the gastrocnemius muscle arterioles. This assertion is 
supported by the fact the NOS blockade significantly increased spontaneous tone in 
all vessels, indicating that under non-stimulated conditions, NO still plays a role in 
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the modulation of basal vasoconstrictor tone in the fatty gastrocnemius muscle 
arterioles despite a lack of stimulated activity.   
A number of possibilities exist to explain this lack of stimulated NO-
mediated vasodilation.  Acute hyperglycemia has been shown to decrease eNOS 
and result in diminished NO production by cultured endothelial cells (57, 59). In 
type 1 diabetic rats, it does not appear that a loss of NOS protein explains 
decrements in NO production, but rather a deficiency in a cofactor necessary for its 
production, tetrahydrobiopterin (72). AGEs in type 2 diabetes may induce oxidative 
stress production or directly quench NO and reduce its ability to relax the smooth 
muscle (17, 26, 119).  At the present time, the precise mechanism inducing the shift 
from endothelial NO to prostaglandin vasodilation is unknown.    
Vasoconstrictor responsiveness was unaltered in the soleus muscle 
arterioles from the prediabetic fatty rats.  However, the gastrocnemius muscle 
arterioles displayed an enhancement in response to the receptor-mediated agonist 
NE with no change in the non-receptor-mediated vasoconstriction to KCl.  A 
possible explanation for this difference may be the loss in stimulated NO 
production.  Nitric oxide is released from the vascular endothelium in response to 
NE activation of the alpha2-adrenoreceptors (40, 117) as well as in response to 
myogenic activation (117).  A loss of this modulating influence to buffer 
vasoconstrictor reactivity may explain the enhancement of vasoconstriction seen 
with these vasoconstrictor stimuli, which is consistent with an unchanged smooth 
muscle response to KCl.  Also possible is a change in the structural properties of 
  
92
the vessel that may alter the mechanical distensibility of the vessels and alter active 
vasoconstrictor behavior. 
The passive pressure-diameter relation, measures of circumferential stress 
and strain and incremental stiffness were assessed to determine the structural 
behavior of the vascular wall.  The passive pressure-diameter relation assesses the 
distensibility of the vessel segment to increases in increasing intraluminal pressure, 
while the circumferential stress and strain and incremental stiffness are calculated 
parameters that assess the mechanical properties of the medial wall in response to 
increases in intraluminal pressure.  In soleus muscle arterioles from prediabetic rats 
there were no changes in the passive pressure-diameter relation.  And even though 
there was no change in medial wall morphology of the soleus muscle arterioles, 
there was an increase in circumferential wall stress in response to increasing 
intraluminal pressure. 
The gastrocnemius muscle arterioles responded to increases in intraluminal 
pressure differently from that of the soleus muscle arterioles, such that at low 
intraluminal pressures the arterioles were more distensible in the fatty rats than 
were those from the lean age-matched controls.  During this stage of diabetes, 
increases in medial wall cross-sectional area and wall-to-lumen ratio were observed 
in the gastrocnemius muscle arterioles of the fatty rats.  Analysis of the 
circumferential stress, strain and incremental stiffness of the gastrocnemius 
arterioles revealed a decreased circumferential strain in response to changes in 
intraluminal pressure.  However, no differences were observed in the slope of the 
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relation of these two characteristics, resulting in no change in vessel wall 
incremental stiffness in prediabetic gastrocnemius muscle arterioles. 
Although elevated arterial pressure is not present in prediabetes, enhanced 
adrenergic vasoconstriction may be predisposing the rats to its development with 
overt diabetes.  Previous investigators have shown sympathetic nerve activity to be 
elevated in response to insulin infusion in normal healthy humans, despite the 
maintenance of normal arterial pressures (32).  Moreover, adrenergic 
vasoconstrictor responses have been shown to be elevated in the forearm of type 2 
diabetic patients in response to norepinephrine administration (49).  A similar 
enhancement in the NE-mediated vasoconstriction was observed in the present 
study.  Interestingly, this enhancement is present only in arterioles from the low-
oxidative glycolytic gastrocnemius muscle, which show a greater level of alpha-
adrenergic than that seen in high-oxidative skeletal muscles (62).  Thus, if 
sympathetic activity is similarly enhanced in the ZDF rat, the combined effect of 
enhanced sympathetic drive and enhanced adrenergic responsiveness would be a 
large increase in vasoconstrictor tone in the arterioles of low-oxidative skeletal 
muscles, which make up approximately 70% of the total skeletal muscle mass (24) 
and may contribute to increased regional vascular resistance and alterations in 
blood flow distribution.  In addition to a role in arterial pressure, these putative 
changes in blood flow distribution could also contribute to an exacerbation of 
insulin resistance by diverting blood away from the skeletal muscle, thereby 
limiting glucose and insulin delivery and thus glucose disposal.  The soleus muscle 
arterioles appear to be largely protected from alterations in function during 
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prediabetes, although increases in circumferential stress may be predisposing these 
arterioles to the altered mechanical properties observed in chronic type 2 diabetes.   
 
5.3 Acute Diabetes 
Maximal vasodilator response to ACh was unaffected by acute diabetes in 
both the soleus or the gastrocnemius muscle arterioles.  However, as occurred 
during prediabetes, the gastrocnemius muscle arterioles lacked the NO component 
of ACh-induced vasodilation that was present in the lean control rats. Nitric oxide 
synthase inhibition through L-NAME produced approximately a 50% reduction in 
vasodilation to ACh in the lean gastrocnemius arterioles, but was without effect in 
arterioles from the fatty rats. Combination blockade with L-NAME and INDO 
reduced the ACh-induced vasodilation in the gastrocnemius muscle arterioles of the 
fatty rats, but failed to further diminish vasodilation in the lean age-matched 
controls beyond what was observed with NOS blockade alone. L-NAME blockade 
produced an increase in spontaneous tone in soleus and gastrocnemius muscles 
arterioles from both the lean and fatty rats at 13 weeks of age.   Thus, the shift from 
NOS to cyclooxygenase appeared to affect stimulated endothelium-dependent 
vasodilation and not basal tone. 
Flow-mediated vasodilation was significantly diminished in the soleus 
muscle arterioles, but unchanged in the gastrocnemius arterioles from diabetic rats 
compared to their lean age-matched controls.  Muller-Delp et al. (2002) (77) and 
Schrage et al. (2002) (98) have previously demonstrated that flow-induced 
vasodilation is mediated through an NO-dependent mechanism in soleus muscle 1A 
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arterioles in Fisher 344 and Sprague-Dawley rats, respectively.  If flow-induced 
vasodilation occurs similarly through a nitroxidergic mechanism in the ZDF rat, 
then a diminished flow-induced vasodilator response with a normal ACh-induced 
vasodilation is indicative of an alteration in the flow sensitive pathway in the 
vascular endothelium upstream of NO production.  Thus, alterations in vessel 
morphology or shear/stretch responsive receptors may be responsible for this 
specific loss of endothelial function. 
Increased vasoconstrictor responsiveness was observed to both KCl and NE 
in the soleus muscle arterioles from the acutely diabetic rats.  However, no changes 
in myogenic vasoconstriction were found in the soleus muscle arterioles during this 
stage in the progression of diabetes.  A different effect was found in the 
gastrocnemius muscle arterioles, with a diminished vasoconstriction to increasing 
concentrations of isotonic KCl in the acutely diabetic gastrocnemius arterioles.  
However, the responsiveness to NE and myogenic vasoconstriction was unaltered 
in the gastrocnemius muscle arterioles of the acutely diabetic rats relative to lean 
age-matched controls, and this lack of change may be the result of a reduced NO-
mediated modulation of the vasoconstriction induced by increasing intraluminal 
pressure and NE.  
No differences in medial wall thickness, cross-sectional area, wall-to-lumen 
ratio, or luminal diameter occurred in arterioles from either muscle in the acutely 
diabetic rats.  A small but significant increase in distensibility to low intraluminal 
pressures occurred in the acutely diabetic soleus muscle arteriolar passive pressure-
diameter relation. However, no changes in the mechanical properties of the vessel 
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wall were found.  Conversely, no changes in the passive pressure-diameter relation 
were found in the gastrocnemius muscle arterioles of the acutely diabetic rats, 
although circumferential stress was increased in these vessels. 
 With the onset of overt diabetes, the external environment of the arterioles 
has been significantly altered such that, hyperinsulinemia is absent and marked 
hyperglycemia and elevated arterial pressure are both present.  In response to these 
stimuli, the arterioles of the high-oxidative soleus muscle demonstrate a greater 
degree of dysfunction than do those of the low-oxidative glycolytic gastrocnemius 
muscle.  For example, the altered adrenergic vasoconstriction that occurred in 
prediabetes in the gastrocnemius is absent and KCl-induced vasoconstriction is 
diminished.  Whereas, in the soleus muscle arterioles, adrenergic and KCl-induced 
vasoconstrictor responsiveness are increased and flow-induced vasodilation is 
decreased.  The combined effect of these alterations in soleus muscle vascular 
function may result in a net increase in vasoconstrictor tone, increased regional 
vascular resistance, and, subsequently, increased mean arterial pressure.  In 
addition, increased passive distention of the soleus muscle arterioles manifests 
during acute diabetes, and appears to be the beginning of altered mechanical 
properties that worsen as the disease is prolonged.  Thus, in acute diabetes 
increases in the vasoconstrictor responses and diminished vasodilator capacity in 
the arterioles of the high-oxidative soleus muscle may predominate, and in the 
presence of largely unaltered structure and function in the low-oxidative glycolytic 
skeletal muscle arterioles, may contribute to the elevations in arterial pressure that 
emerge concurrently with overt disease. 
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5.4 Chronic Diabetes 
 Chronic diabetes resulted in a reduced maximal vasodilator response to both 
ACh and intraluminal flow in the soleus muscle arterioles.  The reduced ACh-
induced vasodilator response is the consequence of a loss of the NOS-dependent 
signaling mechanism.  Vasodilation in the gastrocnemius muscle arterioles 
remained unaffected by diabetes; however, at this age, L-NAME did not reduce the 
vasodilation to ACh in either the lean or fatty rats.   
 Vasoconstrictor responsiveness was unaffected by chronic diabetes in the 
soleus muscle arterioles compared to their age-matched counterparts.   In the 
gastrocnemius muscle, however, despite a diminished responsiveness to KCl (30 
and 40 mM KCl), vasoconstrictor responsiveness to NE and increasing intraluminal 
pressure were both higher. 
 No changes in vessel morphology occurred in either muscle with chronic 
diabetes.  However, the passive pressure-diameter relation, circumferential stress 
and strain, and incremental stiffness revealed changes in the structural 
characteristics and mechanical properties of the vessels.  In arterioles from both the 
soleus and gastrocnemius muscles, the passive pressure-diameter relation differed 
between the fatty and lean rats such that at high intraluminal pressures (77-99 
mmHg) arterioles from both muscles display an increased relative diameter.  In the 
soleus muscle arterioles, both circumferential stresses and strains were increased in 
the fatty rats compared to lean age-matched controls, and the slope of the relations 
indicated a reduction in vessel stiffness in the soleus muscle arterioles from the 
chronically diabetic rats.  Gastrocnemius muscle arterioles from the chronically 
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diabetic rats also showed increased circumferential strains, but no differences were 
found for either circumferential stress or incremental stiffness.  
 With chronic diabetes, the external environment of the arterioles is similar 
to acute diabetes, but the arterioles have been exposed to the elevations in arterial 
pressure and marked hyperglycemia for a prolonged period.  Under these 
conditions, arteriolar dysfunction occurs in both the soleus and gastrocnemius 
muscle arterioles, although altered mechanical properties of the arterioles is more 
pronounced in the soleus muscle arterioles.   Chronic diabetes results in enhanced 
vasoconstrictor responses in the low-oxidative glycolytic gastrocnemius muscle 
arterioles and diminished vasodilator responses in the high-oxidative soleus muscle 
arterioles, the combined effect of which is likely to increase the vascular resistance 
of the skeletal muscle and contribute to the elevated arterial pressure.  Moreover, 
the presence of type 2 diabetes for a prolonged period of time resulted in alterations 
in the passive mechanical properties of both soleus and gastrocnemius muscle 
arterioles, and may be indicative of alterations in the matrix components of the 
arterioles since wall morphology appears unaltered.  Therefore, although chronic 
diabetes appears to present arterioles with a similar external environment to that 
which is experienced in acute diabetes, the prolongation of these stimuli results in 
different arteriolar adaptations than occurred in the acute phase of diabetes. 
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5.5 Endothelial Dysfunction in High-oxidative Skeletal Muscle Arterioles and 
the Emergence of Elevated Mean Arterial Pressure 
The ZDF rat is a particularly useful model of type 2 diabetes, not only 
because of its predictable progression to overt disease, but also because the 
development of diabetes is accompanied by many of the same conditions that 
coexist in type 2 diabetic patients, including the coincidence of elevations of 
arterial pressure.  Hypertension is often present at the time of diagnosis in type 2 
diabetes patients (113), however, the slow, often silent progression of the disease 
may lead many patients to go undiagnosed for long periods of time even after frank 
diabetes has become manifest.  With this model of type 2 diabetes it is possible to 
examine the temporal relation of alterations in arteriolar reactivity and elevations in 
arterial pressure. 
 Obesity and hyperinsulinemia have been associated with increases in 
sympathetic nerve activity (18, 73) and are both associated with the prediabetic 
state.  This increase in sympathetic drive may be differentially affecting arterioles 
from high-oxidative and low-oxidative glycolytic skeletal muscles and contribute to 
endothelial dysfunction associated with overt diabetes.  Responsiveness to NE is 
enhanced only in the gastrocnemius arterioles, setting the stage for a large increase 
in vasoconstriction to an increased NE availability under conditions of elevated 
sympathetic nerve activity.  As previous investigators have shown, arteriolar and 
capillary recruitment in response to both muscular contraction and pharmacological 
agonists can vary between microvessels of similar architecture even within a single 
muscle (69, 109).  It is reasonable to predict that, in the presence of a normal 
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responsiveness to NE and normal myogenic tone in the soleus muscle arterioles, a 
greater than normal percentage of the blood flow may be directed towards the high-
oxidative skeletal muscles or towards other tissue that will not dispose of glucose 
during prediabetes, owing to this enhanced vasoconstrictor tone in the low-
oxidative glycolytic skeletal muscle.  Although a shunting toward the 
predominately high-oxidative soleus muscle could positively affect glucose 
disposal and therefore insulin resistance, it could also increase shear stress in these 
arterioles, increasing endothelial damage and leading to subsequent dysfunction.  
Such a sequence of events is not dissimilar from that proposed in the hemodynamic 
hypothesis of type 1 diabetic vascular complications, in which early increases in 
capillary pressure are proposed to enhance shear stress and lead to endothelial 
dysfunction and structural adaptations in the microcirculation (83).  Endothelial 
dysfunction, as evidenced by reduced flow-induced dilation, is indeed present in 
type 2 diabetes, and is coincident with both the development of overt diabetes and 
elevated mean arterial pressure in this model.  Moreover, this endothelial 
dysfunction persists throughout the progression of the disease, even after 
vasoconstrictor responses have normalized in the same skeletal muscle.  However, 
this endothelial dysfunction appears to be limited to the arterioles of the high-
oxidative soleus muscle. 
 
5.6 Alterations in Arterioles from the Low-oxidative Glycolytic Gastrocnemius 
Muscle 
 Endothelial responses in the gastrocnemius muscle arterioles are protected 
from diabetes-induced dysfunction.  In fact, although there appears to be a loss of 
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the NO-mediated portion of ACh-induced dilation in the prediabetic and diabetic 
arterioles, this defect is compensated for by an increase in the contribution of COX-
1 products.  Moreover, with maturation in the lean animals this NO component to 
ACh-induced vasodilation is normally lost by 20 weeks of age, and neither the 
maximal vasodilation nor mechanisms through which it is achieved differ between 
the diabetic or normal rats.  Thus, abnormal vasodilator responses of the low-
oxidative glycolytic gastrocnemius muscle arterioles do not occur as a result of the 
diabetic state, and therefore this mechanism may not contribute to the elevations in 
mean arterial pressure observed with the onset of overt disease in these rats. 
Despite a normal vasodilator response, both the mechanical properties and 
vasoconstrictor responsiveness of the gastrocnemius muscle arterioles are affected 
by prediabetes, acute and chronic type 2 diabetes.  Alterations in the mechanical 
properties of the gastrocnemius muscle arterioles may contribute to the changes in 
vasoconstrictor responses observed.  Circumferential strain analysis demonstrated a 
progressive increase in wall distensibility during the development of chronic type 2 
diabetes in the gastrocnemius muscle, despite the decreasing strain observed in the 
arterioles from the control rats across these same ages. This increase in the 
distensibility of the vessel may function to limit the contractility of the vascular 
smooth muscle and may be related to the diminished KCl-induced vasoconstriction 
in the acute and chronic diabetic arterioles. 
However, despite lower contractile performance to KCl, these vessels are 
able to achieve normal or even enhanced vasoconstrictor responses to receptor-
mediated agonists.  It is possible that signaling cascades affected by the metabolic 
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derangement of the disease could be upregulated and increase the responsiveness of 
the arterioles to these agonists.  One possible explanation may be protein kinase C 
(PKC) activation.  Increased activation of PKC has been documented as a 
consequence of hyperglycemia and enhanced de novo synthesis of diacylglycerol 
(13, 21, 25).  PKC activation decreases NOS activity leading to a reduced 
production of NO (78), which could result in enhanced constriction to both 
myogenic activation and NE.  Moreover, the cellular activation of the myogenic 
response is itself  PKC-dependent, and increased PKC activation may lead directly 
to the enhanced myogenic tone seen in the present study (20, 116).   
The passive mechanical characteristics may also be influenced by 
alterations in this same signaling molecule.  PKC activation can increase the 
accumulation of extracellular matrix proteins, such as type IV collagen and 
fibronectin, via the induction of transforming growth factor-beta (TGF-β) (13).  
Alterations in the extracellular matrix components of the vessels may result in the 
abnormal passive properties seen in these arterioles. 
In conclusion, during the development of type 2 diabetes, the external 
environment of the skeletal muscle arterioles progresses from hyperinsulinemia and 
mild hyperglycemia to marked hyperglycemia in the absence of hyperinsulinemia 
with concurrent elevations in arterial pressure.  The prediabetic condition results in 
increased adrenergic vasoconstriction in the low-oxidative glycolytic 
gastrocnemius arterioles.  This may result in enhanced regional vascular resistance 
and contribute to the concurrent insulin resistance as well as to the elevations in 
arterial pressure that occurs with acute diabetes.  Acute diabetes results in enhanced 
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vasoconstriction and diminished vasodilation in the high-oxidative skeletal muscle 
arterioles concurrent with the emergence of arterial pressure.  Finally, chronic 
diabetes results in diminished vasodilation of soleus muscle arterioles and 
enhanced vasoconstriction in gastrocnemius arterioles, the combined affect of 
which would likely lead to enhanced regional vascular resistance and contribute to 
the concurrent elevations in arterial pressure.  Moreover, the development of type 2 
diabetes results in a progressive increase in passive distention and circumferential 
strain in arterioles from both skeletal muscle arterioles examined.   
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